Twilio Announces First Quarter 2026 Results

Twilio Announces First Quarter 2026 Results

  • Revenue of$1.41 billion, up 20% reported and 16% organic year-over-year
  • GAAP gross profit of $684 million, up 18% year-over-year
  • Non-GAAP gross profit of $697 million, up 16% year-over-year
  • GAAP Income from Operations of $108 million
  • Non-GAAP Income from Operations of $279 million

SAN FRANCISCO–(BUSINESS WIRE)–
Twilio (NYSE: TWLO), the customer engagement platform that drives real-time, personalized experiences for today’s leading brands, reported financial results for its first quarter ended March 31, 2026.

“Q1 was a milestone quarter for Twilio, marked by our highest revenue and gross profit growth rates in more than three years,” said Khozema Shipchandler, CEO of Twilio. “Twilio’s performance is the result of a multi-year, companywide evolution that fundamentally transformed Twilio’s innovation velocity, GTM efficiency, and financial rigor and has led us to become a foundational infrastructure layer in the era of AI.”

First Quarter 2026 Financial Highlights

  • Revenue of $1.41 billion, up 20% year-over-year. Organic revenue growth was 16% year-over-year.

  • GAAP gross profit of $684.2 million, up 18% year-over-year.

  • Non-GAAP gross profit of $697.5 million, up 16% year-over-year.

  • GAAP income from operations of $107.7 million, up 366% year-over-year.

  • Non-GAAP income from operations of $278.9 million, up 31% year-over-year.

  • GAAP net income per share attributable to common stockholders, diluted, of $0.57 based on 157.8 million weighted average shares outstanding, compared with GAAP net income per share attributable to common stockholders, diluted, of $0.12 based on 161.8 million weighted average shares outstanding in the first quarter of 2025.

  • Non-GAAP net income per share attributable to common stockholders, diluted, of $1.50 based on 157.8 million non-GAAP weighted average shares outstanding, compared with non-GAAP net income per share attributable to common stockholders, diluted, of $1.14 based on 161.8 million non-GAAP weighted average shares outstanding in the first quarter of 2025.

  • Net cash provided by operating activities of $153.2 million and free cash flow of $132.3 million, compared with net cash provided by operating activities of $191.0 million and free cash flow of $178.3 million for the first quarter of 2025.

Key Metrics

  • Dollar-Based Net Expansion Rate of 114% for the first quarter of 2026 compared to Dollar-Based Net Expansion Rate of 107% for the first quarter of 2025.

  • 5,558 employees as of March 31, 2026.

Dollars in millions, except per share amounts

Q1 2026

Results

Revenue

$1,407

Y/Y Revenue Growth

20%

Y/Y Organic Revenue Growth

16%

 

 

 

 

 

Amount

Margin

Y/Y Growth

GAAP gross profit

$684

49%

18%

Non-GAAP gross profit

$697

50%

16%

GAAP income from operations

$108

8%

366%

Non-GAAP income from operations

$279

20%

31%

Net cash provided by operating activities

$153

11%

 

Free cash flow

$132

9%

 

GAAP net income attributable to common stockholders

$90

 

 

Non-GAAP net income attributable to common stockholders

$236

 

 

GAAP net income per share attributable to common stockholders, diluted

$0.57

 

 

Non-GAAP net income per share attributable to common stockholders, diluted

$1.50

 

 

Share Repurchase Program

In January 2025, Twilio’s Board of Directors authorized a share repurchase program pursuant to which Twilio may repurchase up to $2.0 billion in aggregate value of its outstanding Class A common stock (“common stock”). The program is set to expire on December 31, 2027. During the first quarter of 2026, Twilio repurchased $253.4 million in aggregate value of shares of common stock. To date, Twilio has completed approximately $1.1 billion of aggregate repurchases and has $892.0 million of the originally authorized amount available for future repurchases as of March 31, 2026.

Outlook

For the second quarter ended June 30, 2026, Twilio is initiating a revenue range of $1.420 to $1.430 billion, which implies a reported revenue growth range of 15.5% to 16.5% and an organic revenue growth range of 10% to 11% year-over-year. In addition, Twilio is initiating a second quarter non-GAAP income from operations range of $250 to $260 million. Lastly, Twilio expects second quarter non-GAAP diluted earnings per share in a range of $1.27 to $1.32, based on non-GAAP weighted average diluted shares outstanding of 157 million.

Dollars and shares in millions, except per share amounts

 

Q2 2026

Guidance

Revenue

 

$1,420 – $1,430

Y/Y Revenue Growth

 

15.5% – 16.5%

Y/Y Organic Revenue Growth

 

10% – 11%

Non-GAAP income from operations

 

$250 – $260

Non-GAAP diluted earnings per share (1)

 

$1.27 – $1.32

Non-GAAP weighted average diluted shares outstanding

 

157

(1)

Non-GAAP diluted earnings per share guidance assumes no impact from volatility of foreign exchange rates.

For fiscal year 2026, Twilio is raising its reported revenue growth range to 14% to 15% compared with 11.5% to 12.5% previously, and its organic revenue growth range to 9.5% to 10.5% year-over-year compared with 8% to 9% previously. In addition, Twilio expects full-year non-GAAP gross profit growth to be similar to its organic revenue growth range. Lastly, Twilio is raising its 2026 non-GAAP income from operations range to $1.08 billion to $1.10 billion compared to $1.04 billion to $1.06 billion previously, and raising its 2026 free cash flow range to $1.08 billion to $1.10 billion compared to $1.04 billion to $1.06 billion previously.

Dollars in millions

 

FY26

Guidance

Y/Y Revenue Growth

 

14% – 15%

Y/Y Organic Revenue Growth

 

9.5% – 10.5%

Non-GAAP income from operations

 

$1,080 – $1,100

Free cash flow

 

$1,080 – $1,100

Conference Call Information

Twilio is hosting a Q&A conference call today, April 30, 2026, to discuss its first quarter 2026 financial results. The conference call will begin at 2:00 p.m. (PT) / 5:00 p.m. (ET), and investors and analysts should register for the webcast in advance by visiting https://edge.media-server.com/mmc/p/sfj2jo9i. The live webcast of the conference call, as well as a replay, and Twilio’s supplemental earnings presentation, will be available on the investor relations website.

Twilio uses its investor relations website, its X feed (@twilio) and its LinkedIn page as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Twilio Inc.

Today’s leading companies trust Twilio’s Customer Engagement Platform (CEP) to build direct, personalized relationships with their customers everywhere in the world. Twilio enables companies to use communications and data to add intelligence and security to every step of the customer journey, from sales to marketing to growth, customer service and many more engagement use cases in a flexible, programmatic way. Across 180 countries and territories, millions of developers and hundreds of thousands of businesses use Twilio to create magical experiences for their customers. For more information about Twilio (NYSE: TWLO) visit www.twilio.com.

Forward-Looking Statements

This press release and the accompanying conference call contain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,” “can,” “will,” “would,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “forecasts,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements contained in this press release and the accompanying conference call include, but are not limited to, statements about: our future financial and operating performance and outlook, including our expected financial and operating results, guidance and targets, including the assumptions underlying such guidance and targets; our anticipated strategies and business plans and our ability to successfully execute them; our ability to drive growth, profitability and free cash flow; our ability to maintain cost discipline and drive operating leverage; future investments and expenses; our expectations regarding carrier fees, and our related actions, and the impact of such fees on our financial and operating performance, including guidance; our expectations regarding our margins, including regarding price actions, product mix and growth in higher-margin products; our expectations regarding capital returns to shareholders, including share repurchases; our expectations regarding revenue from ISVs and self-serve customers; our expectations regarding our cross-sell, upsell and solution selling efforts; our pipeline of new business; the benefits our customers derive from our products; our ability to expand into new and existing markets; our innovation roadmap and the development, release and adoption of our products (and the timing thereof); the effects of our go-to-market efforts to drive profitable growth and capture market share; our expectations related to being a foundational infrastructure layer in the AI era; our expectations regarding our upcoming SIGNAL conference; and our expectations regarding the macroeconomic environment. You should not rely upon forward-looking statements as predictions of future events.

The outcome of the events described in these forward-looking statements is subject to known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to differ materially from those described in the forward-looking statements, including, among other things: the impact of global economic and political conditions and uncertainties; the accuracy of our forecasts and metrics; fluctuations in our results of operations and the levels of our customers’ usage of our platform; our ability to attract and retain customers and expand their usage of our platform; our ability to develop new products and integrate our products with third-party products effectively; our ability to manage our growth and strategic changes to our business; our ability to compete effectively in intensely competitive markets; the occurrence of and our ability to manage cybersecurity breaches and other incidents impacting our networks and systems or those of our third-party service providers; our ability to manage changes in network service provider fees and optimize our network service provider coverage and connectivity; and our compliance with industry standards, laws and regulations.

The forward-looking statements contained in this press release and the accompanying conference call are also subject to additional risks, uncertainties, and factors, including those more fully described in our most recent filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Should any of these risks materialize, or should our assumptions prove to be incorrect, actual financial results could differ materially from our projections or those implied by these forward-looking statements. Moreover, we operate in a very competitive and rapidly changing environment, and new risks and uncertainties may emerge that could have an impact on the forward-looking statements contained in this press release and the accompanying conference call.

All forward-looking statements contained in this press release and the accompanying conference call represent our management’s beliefs and assumptions only as of the date such statements are made and we do not assume any obligation to update any forward-looking statements to reflect events or circumstances occurring after the date on which the statements were made, or to reflect new information or the occurrence of unanticipated events, except as required by law.

Non-GAAP Financial Measures

In addition to financial information presented in accordance with U.S. generally accepted accounting principles (“GAAP”), this press release and the accompanying conference call include certain non-GAAP financial measures, including those listed below. We use these non-GAAP financial measures to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that these non-GAAP financial measures may be helpful to investors because they provide consistency and comparability with past financial performance, facilitate period-to-period comparisons of results of operations and assist in comparisons with other companies, many of which use similar non-GAAP financial measures to supplement their GAAP results. We believe organic revenue and organic revenue growth are useful in understanding the ongoing results of our operations. We believe free cash flow and free cash flow margin provide useful supplemental information to help investors understand underlying trends in our business and our liquidity.

These non-GAAP financial measures are presented for supplemental informational purposes only, should not be considered substitutes for financial information presented in accordance with GAAP, and may be different from similarly-titled non-GAAP measures used by other companies. A reconciliation of these measures to the most directly comparable GAAP measures is included at the end of this press release. We have not provided the forward-looking GAAP equivalents for certain forward-looking non-GAAP measures presented in this press release and the accompanying conference call, or a GAAP reconciliation, as a result of the uncertainty regarding, and the potential variability of, reconciling items such as stock-based compensation expense. Accordingly, a reconciliation of these non-GAAP guidance metrics to their corresponding forward-looking GAAP equivalents is not available without unreasonable effort. However, it is important to note that material changes to reconciling items could have a significant effect on future GAAP results.

Non‑GAAP Gross Profit and Non‑GAAP Gross Margin. For the periods presented, we define non‑GAAP gross profit and non‑GAAP gross margin as GAAP gross profit and GAAP gross margin, respectively, adjusted to exclude stock-based compensation, amortization of acquired intangibles and payroll taxes related to stock-based compensation.

Non‑GAAP Income (Loss) from Operations and Non‑GAAP Operating Margin. For the periods presented, we define non‑GAAP income (loss) from operations and non‑GAAP operating margin as GAAP income (loss) from operations and GAAP operating margin, respectively, adjusted to exclude, as applicable, stock-based compensation, amortization of acquired intangibles, loss on net assets divested, acquisition and divestiture related expenses, payroll taxes related to stock-based compensation, charitable contributions, restructuring costs, impairment of long-lived assets, and gains or losses on lease termination.

Non‑GAAP Net Income Attributable to Common Stockholders and Non‑GAAP Net Income Per Share Attributable to Common Stockholders. For the periods presented, we define non-GAAP net income attributable to common stockholders and non‑GAAP net income per share attributable to common stockholders, diluted (which we refer to as “non-GAAP diluted earnings per share”) as GAAP net income (loss) attributable to common stockholders and GAAP net income (loss) per share attributable to common stockholders, diluted, respectively, adjusted to exclude, as applicable, stock-based compensation, amortization of acquired intangibles, loss on net assets divested, acquisition and divestiture related expenses, losses (gains) on strategic investments, payroll taxes related to stock-based compensation, accretion of debt discount and issuance costs, provision of income tax effects related to non-GAAP adjustments, income tax benefit related to acquisitions, charitable contributions, share of losses from equity method investment, impairment of equity method investment, restructuring costs, impairment of long-lived assets, gains or losses on or impairment of strategic investments, and gains or losses on lease termination.

Organic Revenue. For the periods presented, we define organic revenue as GAAP revenue, excluding (i) revenue from each acquired business and revenue from incremental increases to application-to-person (“A2P”) fees imposed by major U.S. carriers on our core messaging business, in each case until the beginning of the first full quarter following the one-year anniversary of the closing date of such acquisition or the initial date such fees were charged and (ii) revenue from each divested business beginning in the quarter of the closing date of such divestiture; provided that (a) if an acquisition closes or such fees are initially charged on the first day of a quarter, such revenue will be included in organic revenue beginning on the one-year anniversary of the closing date of such acquisition or the initial date such fees were charged and (b) if a divestiture closes on the last day of a quarter, such revenue will be included in organic revenue for that quarter. As used in this definition, A2P fees refers to fees imposed by U.S. mobile carriers for A2P messages delivered to their subscribers, and we pass these fees to our messaging customers at cost.

Organic Revenue Growth. For the periods presented, we calculate organic revenue growth by dividing (i) organic revenue for the period presented less organic revenue in the comparative period by (ii) organic revenue in the comparative period. If revenue from certain acquisitions, divestitures or A2P fees is included or excluded in organic revenue in the period presented, then revenue from the same acquisitions, divestitures and A2P fees is included or excluded in organic revenue in the comparative period for purposes of the organic revenue growth calculation. As a result, organic revenue used in this calculation for the comparative period will not always equal organic revenue reported for the comparative period.

Free Cash Flow and Free Cash Flow Margin. For the periods presented, we define free cash flow as net cash provided by operating activities, excluding capitalized software development costs and purchases of long-lived assets, and we define free cash flow margin as free cash flow divided by revenue.

Operating Metrics

We review a number of operational and financial metrics, including Dollar-Based Net Expansion Rate (“DBNE”), to evaluate our business, measure our performance, identify trends affecting our business, formulate business plans and make strategic decisions. Our DBNE is not based on any standardized industry methodology and is not necessarily calculated in the same manner or comparable to similarly titled measures presented by other companies. Similarly, our DBNE may differ from estimates published by third parties or from similarly titled metrics of our competitors due to differences in methodology. The numbers that we use to calculate DBNE are based on internal data. While these numbers are based on what we believe to be reasonable judgments and estimates for the applicable period of measurement, there are inherent challenges in measuring usage. We regularly review and may adjust our processes for calculating our internal metrics to improve their accuracy. If investors or analysts do not perceive our metrics to be accurate representations of our business, or if we discover material inaccuracies in our metrics, our reputation, business, results of operations, and financial condition would be harmed.

Beginning in the first quarter of 2026, we have discontinued disclosure of Active Customer Accounts as a key metric. As a result, we are revising the definition of DBNE to remove references to Active Customer Accounts and Zipwhip accounts and instead refer to “customer accounts.” The methodology for identifying these customer accounts is unchanged from the methodology most recently used to identify Active Customer Accounts and this definitional update has no impact on our methodology for calculating DBNE or our historical or future DBNE.

Dollar-Based Net Expansion Rate. Our DBNE compares the total revenue in a quarter from all individual customer accounts, as identified by a unique account identifier, for which we have recognized at least $5 of revenue in the last month of the quarter, to revenue from those same accounts in the same quarter in the prior year. A single customer organization may constitute multiple unique customer accounts if it has multiple account identifiers. To calculate DBNE, we first identify the cohort of such customer accounts in the same quarter of the prior year. DBNE is the quotient obtained by dividing the revenue generated from that cohort in a quarter, by the revenue generated from that same cohort in the corresponding quarter in the prior year. When we calculate DBNE for periods longer than one quarter, we use the average of the applicable quarterly DBNEs for each of the quarters in such period. Revenue from acquisitions does not impact the DBNE calculation until the quarter following the one-year anniversary of the applicable acquisition, unless the acquisition closing date is the first day of a quarter. Revenue from divestitures does not impact the DBNE calculation beginning in the quarter the divestiture closed, unless the divestiture closing date is the last day of a quarter.

We believe that measuring DBNE provides an important indication of the performance of our efforts to increase revenue from existing customers. Our ability to drive growth and generate incremental revenue depends, in part, on our ability to maintain and grow our relationships with existing customers and to increase their use of the platform. An important way in which we have historically tracked performance in this area is by measuring the DBNE for such customer accounts. Our DBNE increases when these customers increase their usage of a product, extend their usage of a product to new applications or adopt a new product. Our DBNE decreases when these customers cease or reduce their usage of a product or when we lower usage prices on a product. As our customers grow their businesses and extend the use of our platform, they sometimes create multiple customer accounts with us for operational or other reasons. As such, when we identify a significant customer organization (defined as a single customer organization generating more than 1% of revenue in a quarterly reporting period) that has created a new customer account, this new account is tied to, and revenue from this new account is included with, the original customer account for the purposes of calculating this metric.

Source: Twilio Inc.

TWILIO INC.

Condensed Consolidated Statements of Operations

(In thousands, except share and per share amounts)

(Unaudited)

 

 

 

Three Months Ended

March 31,

 

 

2026

 

2025

Revenue

 

$

1,406,907

 

 

$

1,172,463

 

Cost of revenue

 

 

722,663

 

 

 

590,896

 

Gross profit

 

 

684,244

 

 

 

581,567

 

Operating expenses:

 

 

 

 

Research and development

 

 

262,166

 

 

 

254,295

 

Sales and marketing

 

 

211,866

 

 

 

212,113

 

General and administrative

 

 

102,546

 

 

 

92,077

 

Total operating expenses

 

 

576,578

 

 

 

558,485

 

Income from operations

 

 

107,666

 

 

 

23,082

 

Other (expenses) income, net:

 

 

 

 

Share of losses from equity method investment

 

 

(27,223

)

 

 

(19,471

)

Other income, net

 

 

21,789

 

 

 

22,973

 

Total other (expenses) income, net

 

 

(5,434

)

 

 

3,502

 

Income before provision for income taxes

 

 

102,232

 

 

 

26,584

 

Provision for income taxes

 

 

(12,093

)

 

 

(6,567

)

Net income attributable to common stockholders

 

$

90,139

 

 

$

20,017

 

Net income per share attributable to common stockholders:

 

 

 

 

Basic

 

$

0.59

 

 

$

0.13

 

Diluted

 

$

0.57

 

 

$

0.12

 

Weighted-average shares used to compute net income per share attributable to common stockholders:

 

 

 

 

Basic

 

 

152,424,306

 

 

 

153,345,192

 

Diluted

 

 

157,759,141

 

 

 

161,794,287

 

TWILIO INC.

Condensed Consolidated Balance Sheets

(In thousands)

(Unaudited)

 

 

 

As of March 31,

 

As of December 31,

 

 

2026

 

2025

ASSETS

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

 

$

541,976

 

 

$

682,335

 

Short-term marketable securities

 

 

1,804,286

 

 

 

1,788,007

 

Accounts receivable, net

 

 

710,516

 

 

 

636,736

 

Prepaid expenses and other current assets

 

 

390,041

 

 

 

469,650

 

Total current assets

 

 

3,446,819

 

 

 

3,576,728

 

Property and equipment, net

 

 

181,388

 

 

 

176,963

 

Operating right-of-use assets

 

 

29,561

 

 

 

39,031

 

Equity method investment

 

 

275,093

 

 

 

301,642

 

Intangible assets, net

 

 

125,399

 

 

 

142,065

 

Goodwill

 

 

5,292,457

 

 

 

5,291,787

 

Other long-term assets

 

 

226,088

 

 

 

242,674

 

Total assets

 

$

9,576,805

 

 

$

9,770,890

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

Current liabilities:

 

 

 

 

Accounts payable

 

$

91,706

 

 

$

85,089

 

Accrued expenses and other current liabilities

 

 

456,931

 

 

 

608,119

 

Deferred revenue and customer deposits

 

 

159,569

 

 

 

158,677

 

Operating lease liability, current

 

 

32,119

 

 

 

35,123

 

Total current liabilities

 

 

740,325

 

 

 

887,008

 

Operating lease liability, noncurrent

 

 

43,290

 

 

 

54,162

 

Long-term debt, net

 

 

992,722

 

 

 

992,287

 

Other long-term liabilities

 

 

16,384

 

 

 

15,887

 

Total liabilities

 

 

1,792,721

 

 

 

1,949,344

 

Commitments and contingencies

 

 

 

 

Stockholders’ equity:

 

 

 

 

Preferred stock

 

 

 

 

 

 

Common stock

 

 

152

 

 

 

152

 

Additional paid-in capital

 

 

16,294,528

 

 

 

16,148,190

 

Accumulated other comprehensive (loss) income

 

 

(4,317

)

 

 

15,668

 

Accumulated deficit

 

 

(8,506,279

)

 

 

(8,342,464

)

Total stockholders’ equity

 

 

7,784,084

 

 

 

7,821,546

 

Total liabilities and stockholders’ equity

 

$

9,576,805

 

 

$

9,770,890

 

TWILIO INC.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

 

 

Three Months Ended

March 31,

 

 

2026

 

2025

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

Net income

 

$

90,139

 

 

$

20,017

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

Depreciation and amortization

 

 

34,167

 

 

 

49,565

 

Non-cash reduction to the right-of-use asset

 

 

4,715

 

 

 

5,170

 

Net amortization of investment premium and discount

 

 

(2,122

)

 

 

(4,314

)

Stock-based compensation

 

 

136,511

 

 

 

139,273

 

Amortization of deferred commissions

 

 

17,139

 

 

 

19,265

 

Unrealized (gains) losses on marketable equity securities

 

 

(4,795

)

 

 

750

 

Share of losses from equity method investment

 

 

27,223

 

 

 

19,471

 

Other adjustments

 

 

10,426

 

 

 

7,549

 

Changes in operating assets and liabilities:

 

 

 

 

Accounts receivable

 

 

(74,869

)

 

 

8,463

 

Prepaid expenses and other current assets

 

 

75,414

 

 

 

33,519

 

Other long-term assets

 

 

(3,175

)

 

 

(9,416

)

Accounts payable

 

 

6,502

 

 

 

7,853

 

Accrued expenses and other current liabilities

 

 

(155,755

)

 

 

(94,262

)

Deferred revenue and customer deposits

 

 

892

 

 

 

(1,634

)

Operating lease liabilities

 

 

(9,096

)

 

 

(10,306

)

Other long-term liabilities

 

 

(110

)

 

 

79

 

Net cash provided by operating activities

 

 

153,206

 

 

 

191,042

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

Acquisitions, net of cash acquired and payments related to prior period acquisitions

 

 

(685

)

 

 

 

Purchases of marketable securities and other investments

 

 

(353,288

)

 

 

(213,844

)

Proceeds from sales and maturities of marketable securities and other investments

 

 

333,644

 

 

 

207,431

 

Capitalized software development costs

 

 

(16,708

)

 

 

(11,564

)

Purchases of long-lived assets

 

 

(4,153

)

 

 

(1,163

)

Net cash used in investing activities

 

 

(41,190

)

 

 

(19,140

)

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

Principal payments on finance leases

 

 

(64

)

 

 

(2,251

)

Value of equity awards withheld for tax liabilities

 

 

(42

)

 

 

(53

)

Repurchases of shares of Class A common stock and related costs

 

 

(253,027

)

 

 

(126,256

)

Proceeds from exercises of stock options

 

 

559

 

 

 

2,766

 

Net cash used in financing activities

 

 

(252,574

)

 

 

(125,794

)

NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

 

 

(140,558

)

 

 

46,108

 

CASH, CASH EQUIVALENTS AND RESTRICTED CASH—Beginning of period

 

 

682,534

 

 

 

431,437

 

CASH, CASH EQUIVALENTS AND RESTRICTED CASH —End of period

 

$

541,976

 

 

$

477,545

 

TWILIO INC.

Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures

(In thousands, except shares, per share amounts and percentages)

(Unaudited)

 

 

 

Three Months Ended March 31,

 

 

2026

 

2025

GAAP gross profit

 

$

684,244

 

 

$

581,567

 

GAAP gross profit growth (Y/Y)

 

 

18

%

 

 

GAAP gross margin

 

 

49

%

 

 

50

%

Non-GAAP adjustments:

 

 

 

 

Stock-based compensation

 

 

3,374

 

 

 

4,271

 

Amortization of acquired intangibles

 

 

9,356

 

 

 

15,682

 

Payroll taxes related to stock-based compensation

 

 

522

 

 

 

482

 

Non-GAAP gross profit

 

$

697,496

 

 

$

602,002

 

Non-GAAP gross profit growth (Y/Y)

 

 

16

%

 

 

Non-GAAP gross margin

 

 

50

%

 

 

51

%

 

 

Three Months Ended March 31,

 

 

2026

 

2025

GAAP income from operations

 

$

107,666

 

 

$

23,082

 

GAAP income from operations growth (Y/Y)

 

 

366

%

 

 

GAAP operating margin

 

 

8

%

 

 

2

%

Non-GAAP adjustments:

 

 

 

 

Stock-based compensation

 

 

136,428

 

 

 

137,520

 

Amortization of acquired intangibles

 

 

16,617

 

 

 

27,139

 

Acquisition related expenses

 

 

122

 

 

 

 

Payroll taxes related to stock-based compensation

 

 

11,926

 

 

 

11,200

 

Charitable contributions

 

 

3,445

 

 

 

2,776

 

Restructuring costs

 

 

2,223

 

 

 

11,691

 

Loss on lease termination

 

 

500

 

 

 

 

Non-GAAP income from operations

 

$

278,927

 

 

$

213,408

 

Non-GAAP income from operations growth (Y/Y)

 

 

31

%

 

 

Non-GAAP operating margin

 

 

20

%

 

 

18

%

 

 

Three Months Ended March 31,

 

 

2026

 

2025

GAAP net income attributable to common stockholders

 

$

90,139

 

 

$

20,017

 

Non-GAAP adjustments:

 

 

 

 

Stock-based compensation

 

 

136,428

 

 

 

137,520

 

Amortization of acquired intangibles

 

 

16,617

 

 

 

27,139

 

Acquisition and divestiture related expenses

 

 

122

 

 

 

 

Payroll taxes related to stock-based compensation

 

 

11,926

 

 

 

11,200

 

Accretion of debt discount and issuance costs

 

 

435

 

 

 

419

 

Provision of income tax effects related to non-GAAP adjustments

 

 

(54,612

)

 

 

(45,318

)

Charitable contributions

 

 

3,445

 

 

 

2,776

 

Share of losses from equity method investment

 

 

27,223

 

 

 

19,471

 

Restructuring costs

 

 

2,223

 

 

 

11,691

 

Losses (gains) on strategic investments, net

 

 

2,052

 

 

 

(959

)

Loss on lease termination

 

 

500

 

 

 

 

Non-GAAP net income attributable to common stockholders

 

$

236,498

 

 

$

183,956

 

TWILIO INC.

Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures

(In thousands, except shares, per share amounts and percentages)

(Unaudited)

 

 

 

Three Months Ended March 31,

 

 

2026

 

2025

GAAP net income per share attributable to common stockholders, diluted*

 

$

0.57

 

 

$

0.12

 

Non-GAAP adjustments:

 

 

 

 

Stock-based compensation

 

 

0.86

 

 

 

0.85

 

Amortization of acquired intangibles

 

 

0.11

 

 

 

0.17

 

Acquisition related expenses

 

 

 

 

 

 

Payroll taxes related to stock-based compensation

 

 

0.08

 

 

 

0.07

 

Accretion of debt discount and issuance costs

 

 

 

 

 

 

Provision of income tax effects related to non-GAAP adjustments

 

 

(0.35

)

 

 

(0.28

)

Charitable contributions

 

 

0.02

 

 

 

0.02

 

Share of losses from equity method investment

 

 

0.17

 

 

 

0.12

 

Restructuring costs

 

 

0.01

 

 

 

0.07

 

Losses (gains) on strategic investments, net

 

 

0.01

 

 

 

(0.01

)

Loss on lease termination

 

 

 

 

 

 

Non-GAAP net income per share attributable to common stockholders, diluted

 

$

1.50

 

 

$

1.14

 

 

 

 

 

 

Weighted-average shares used to compute non-GAAP net income per share attributable to common stockholders, diluted

 

 

157,759,141

 

 

 

161,794,287

 

* Some columns may not add due to rounding

TWILIO INC.

Reconciliation to Non-GAAP Financial Measures

(In thousands, except percentages)

(Unaudited)

 

 

 

Three Months Ended

March 31,

 

 

2026

Organic Revenue

 

 

GAAP Revenue

 

$

1,406,907

 

A2P Revenue

 

 

(46,077

)

Acquisition Revenue

 

 

(1,646

)

Organic Revenue

 

$

1,359,184

 

GAAP Revenue Y/Y Growth

 

 

20

%

Organic Revenue Y/Y Growth

 

 

16%1

 

¹ Organic revenue for the three months ended March 31, 2025, when used as the denominator for Organic Revenue Growth for the three months ended March 31, 2026, is equal to reported revenue. Revenue for the three months ended March 31, 2025 was $1.17 billion.

 

 

Three Months Ended

March 31,

 

 

2026

 

2025

Free cash flow

 

 

 

 

Net cash provided by operating activities

 

$

153,206

 

 

$

191,042

 

Operating cash flow margin

 

 

11

%

 

 

16

%

Non-GAAP adjustments:

 

 

 

 

Capitalized software development costs

 

 

(16,708

)

 

 

(11,564

)

Purchase of long-lived assets

 

 

(4,153

)

 

 

(1,163

)

Free cash flow

 

$

132,345

 

 

$

178,315

 

Free cash flow margin

 

 

9

%

 

 

15

%

Net cash used in investing activities

 

$

(41,190

)

 

$

(19,140

)

Net cash used in financing activities

 

$

(252,574

)

 

$

(125,794

)

TWILIO INC.

Supplemental Stock-Based Compensation Expense Information

(In thousands)

(Unaudited)

 

 

 

Three Months Ended

March 31,

 

 

2026

 

2025

 

 

(In thousands)

Stock-Based Compensation Expense

 

 

 

 

Cost of revenue

 

$

3,374

 

 

$

4,271

 

Research and development

 

 

73,011

 

 

 

78,066

 

Sales and marketing

 

 

31,149

 

 

 

31,359

 

General and administrative

 

 

28,977

 

 

 

25,577

 

Total

 

$

136,511

 

 

$

139,273

 

Stock-Based Compensation Expense as a % of Revenue

 

 

10

%

 

 

12

%

 

Investor Contact:

Rodney Nelson

[email protected]

or

Media Contact:

Caitlin Epstein

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Software Technology Data Management Security

MEDIA:

Logo
Logo

Trupanion Reports First Quarter 2026 Results

SEATTLE, April 30, 2026 (GLOBE NEWSWIRE) — Trupanion, Inc. (Nasdaq: TRUP), a leading provider of medical insurance for cats and dogs, today announced financial results for the first quarter ended March 31, 2026. 

“The gap between the cost of veterinary care and what pet parents can reasonably plan for continues to widen,” said Margi Tooth, Chief Executive Officer and President of Trupanion. “Trupanion is uniquely positioned to meet this moment. Fueled by strong, compounding growth in discretionary profit, we are investing with discipline to broaden our offering, strengthen our competitive positioning, expand choice, and create enduring value for pet parents, veterinarians, and shareholders.”

First Quarter 2026 Financial and Business Highlights

  • Total revenue was $384.0 million, an increase of 12% compared to the first quarter of 2025.
  • Total enrolled pets (including pets from our other business segment) was 1,637,665 at March 31, 2026, a decrease of 2% over March 31, 2025.
  • Subscription business revenue was $269.5 million, an increase of 16% compared to the first quarter of 2025.
  • Subscription enrolled pets was 1,105,783 at March 31, 2026, an increase of 5% over March 31, 2025.
  • Net income was $4.9 million, or $0.11 per basic and diluted share, compared to net income of $(1.5) million, or $(0.03) per basic and diluted share, in the first quarter of 2025.
  • Adjusted EBITDA was $17.4 million, compared to adjusted EBITDA of $12.2 million in the first quarter of 2025.
  • Operating cash flow was $14.6 million and free cash flow was $13.7 million in the first quarter of 2026. This compared to operating cash flow of $16.0 million and free cash flow of $14.0 million in the first quarter of 2025.
  • At March 31, 2026, the Company held $383.7 million in cash and short-term investments with an additional $5.0 million available under its credit facility.

Conference Call

Trupanion’s management will host a conference call today to review its first quarter 2026 results. The call is scheduled to begin shortly after 1:30 p.m. PT/ 4:30 p.m. ET. A live webcast will be accessible through the Investor Relations section of Trupanion’s website at https://investors.trupanion.com/ and will be archived online for 3 months upon completion of the conference call. Participants can access the conference call by dialing 1-844-676-1342 (United States) or 1-412-634-6683 (International). A telephonic replay of the call will also be available after the completion of the call, by dialing 1-844-512-2921 (United States) or 1-412-317-6671 (International) and entering the replay pin number: 10207244.

About Trupanion

Trupanion is a leader in medical insurance for cats and dogs throughout the United States, Canada, and certain countries in Continental Europe with over 1,100,000 pets currently enrolled. For over two decades, Trupanion has given pet owners peace of mind so they can focus on their pet’s recovery, not financial stress. Trupanion is committed to providing pet parents with the highest value in pet medical insurance with unlimited payouts on eligible expenses for the life of their pets. With its patented process, Trupanion is the only North American provider with the technology to pay veterinarians directly in seconds at the time of checkout. Trupanion is listed on NASDAQ under the symbol “TRUP”. The company was founded in 2000 and is headquartered in Seattle, WA. Trupanion policies are issued, in the United States, by its wholly-owned insurance entity American Pet Insurance Company or ZPIC Insurance Company and, in Canada, by its wholly-owned insurance entity GPIC Insurance Company or by Accelerant Insurance Company of Canada. For more information, please visit trupanion.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 relating to, among other things, expectations, plans, prospects and financial results for Trupanion, including, but not limited to, its expectations regarding its ability to continue to grow its enrollments and revenue, and otherwise execute its business plan. These forward-looking statements are based upon the current expectations and beliefs of Trupanion’s management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements made in this press release are based on information available to Trupanion as of the date hereof, and Trupanion has no obligation to update these forward-looking statements.

In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the ability to achieve or maintain profitability and/or appropriate levels of cash flow in future periods; the ability to keep growing our membership base and revenue; the accuracy of assumptions used in determining appropriate member acquisition expenditures; the severity and frequency of claims; the ability to maintain high retention rates; the accuracy of assumptions used in pricing medical plan subscriptions and the ability to accurately estimate the impact of new products or offerings on claims frequency; actual claims expense exceeding estimates; regulatory and other constraints on the ability to institute, or the decision to otherwise delay, pricing modifications in response to changes in actual or estimated claims expense; the effectiveness and statutory or regulatory compliance of our Territory Partner model and of our Territory Partners, veterinarians and other third parties in recommending medical plan subscriptions to potential members; the ability to retain existing Territory Partners and increase the number of Territory Partners and active hospitals; compliance by us and those referring us members with laws and regulations that apply to our business, including the sale of a pet medical plan; the ability to maintain the security of our data; fluctuations in currency exchange rates; the ability to protect our proprietary and member information; the ability to maintain our culture and team; the ability to maintain the requisite amount of risk-based capital; our ability to implement and maintain effective controls; the ability to protect and enforce Trupanion’s intellectual property rights; the ability to successfully implement our alliance with Aflac; the ability to continue key contractual relationships with third parties; third-party claims including litigation and regulatory actions; the ability to recognize benefits from investments in new solutions and enhancements to Trupanion’s technology platform and website; our ability to retain key personnel; and deliberations and determinations by the Trupanion board based on the future performance of the company or otherwise.

For a detailed discussion of these and other cautionary statements, please refer to the risk factors discussed in filings with the Securities and Exchange Commission (SEC), including but not limited to, Trupanion’s Annual Report on Form 10-K for the year ended December 31, 2025 and any subsequently filed reports on Forms 10-Q, 10-K and 8-K. All documents are available through the SEC’s Electronic Data Gathering Analysis and Retrieval system at https://www.sec.gov or the Investor Relations section of Trupanion’s website at https://investors.trupanion.com.

Non-GAAP Financial Measures

Trupanion’s stated results include certain non-GAAP financial measures. These non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in its industry as other companies in its industry may calculate or use non-GAAP financial measures differently. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies and exclude expenses that may have a material impact on Trupanion’s reported financial results. The presentation and utilization of non-GAAP financial measures is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP. Trupanion urges its investors to review the reconciliation of its non-GAAP financial measures to the most directly comparable GAAP financial measures in its consolidated financial statements, and not to rely on any single financial or operating measure to evaluate its business. These reconciliations are included below and on Trupanion’s Investor Relations website.

Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a company’s non-cash expenses, Trupanion believes that providing various non-GAAP financial measures that exclude stock-based compensation expense and depreciation and amortization expense allows for more meaningful comparisons between its operating results from period to period. Trupanion offsets new pet acquisition expense with sign-up fee revenue in the calculation of net acquisition cost because it collects sign-up fee revenue from new members at the time of enrollment and considers it to be an offset to a portion of Trupanion’s new pet acquisition expense. Trupanion believes this allows it to calculate and present financial measures in a consistent manner across periods. Trupanion’s management believes that the non-GAAP financial measures and the related financial measures derived from them are important tools for financial and operational decision-making and for evaluating operating results over different periods of time.

Trupanion, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except share data)
 
  Three Months Ended
March 31,
 
    2026       2025    
  (unaudited)  
Revenue:        
Subscription business $ 269,454     $ 233,064    
Other business   114,595       108,911    
Total revenue   384,049       341,975    
Cost of revenue:        
Subscription business   216,452       189,845    
Other business   106,108       101,027    
Total cost of revenue(1), (2)   322,560       290,872    
Operating expenses:        
Technology and development(1)   11,294       8,072    
General and administrative(1)   19,102       19,892    
New pet acquisition expense(1)   22,611       20,516    
Depreciation and amortization   3,706       3,791    
Total operating expenses   56,713       52,271    
Loss from investment in joint venture         (305 )  
Operating income (loss)   4,776       (1,473 )  
Interest expense   1,875       3,211    
Other (income), net   (3,055 )     (3,240 )  
Income (loss) before income taxes   5,956       (1,444 )  
Income tax expense   1,076       39    
Net income (loss) $ 4,880     $ (1,483 )  
         
Net income (loss) per share:        
Basic $ 0.11     $ (0.03 )  
Diluted $ 0.11     $ (0.03 )  
Weighted average shares of common stock outstanding:        
Basic   43,505,604       42,775,955    
Diluted   43,681,740       42,775,955    
         
(1)Includes stock-based compensation expense as follows: Three Months Ended March 31,  
 
    2026       2025    
Veterinary invoice expense $ 560     $ 770    
Other cost of revenue   569       489    
Technology and development   1,507       1,151    
General and administrative   4,893       4,528    
New pet acquisition expense   1,471       2,892    
Total stock-based compensation expense $ 9,000     $ 9,830    
         
(2)The breakout of cost of revenue between veterinary invoice expense and other cost of revenue is as follows:  
  Three Months Ended March 31,  
    2026       2025    
Veterinary invoice expense $ 281,436     $ 247,450    
Other cost of revenue   41,124       43,422    
Total cost of revenue $ 322,560     $ 290,872    

Trupanion, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share data)
  March 31,
2026
  December 31,
2025
  (unaudited)    
Assets      
Current assets:      
Cash and cash equivalents $ 153,456     $ 138,024  
Short-term investments   230,205       232,706  
Accounts and other receivables, net of allowance for credit losses of $2,419 at March 31, 2026 and $1,311 at December 31, 2025   304,796       301,945  
Prepaid expenses and other assets   16,709       18,387  
Total current assets   705,166       691,062  
Restricted cash   29,416       33,434  
Long-term investments   986       983  
Property, equipment, and internal-use software, net   102,612       104,844  
Intangible assets, net   23,684       24,102  
Other long-term assets   21,095       21,237  
Goodwill   38,621       39,382  
Total assets $ 921,580     $ 915,044  
Liabilities and stockholders’ equity      
Current liabilities:      
Accounts payable $ 12,828     $ 16,445  
Accrued liabilities and other current liabilities   42,329       56,509  
Reserve for veterinary invoices   56,701       55,921  
Deferred revenue   286,508       270,935  
Long-term debt – current portion   10,000       10,000  
Total current liabilities   408,366       409,810  
Long-term debt   99,346       101,784  
Deferred tax liabilities   955       1,510  
Other liabilities   18,091       18,004  
Total liabilities   526,758       531,108  
Stockholders’ equity:      
Common stock: $0.00001 par value per share, 100,000,000 shares authorized; 44,648,800 and 43,620,614 issued and outstanding at March 31, 2026; 44,430,267 and 43,402,081 shares issued and outstanding at December 31, 2025          
Preferred stock: $0.00001 par value per share, 10,000,000 shares authorized; no shares issued and outstanding          
Additional paid-in capital   613,624       604,828  
Accumulated other comprehensive income (loss)   (693 )     2,097  
Accumulated deficit   (201,575 )     (206,455 )
Treasury stock, at cost: 1,028,186 shares at March 31, 2026 and December 31, 2025   (16,534 )     (16,534 )
Total stockholders’ equity   394,822       383,936  
Total liabilities and stockholders’ equity $ 921,580     $ 915,044  

Trupanion, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)
  Three Months Ended March 31,
    2026       2025  
  (unaudited)
Operating activities      
Net income (loss) $ 4,880     $ (1,483 )
Adjustments to reconcile net income (loss) to cash provided by operating activities:      
Depreciation and amortization   3,706       3,791  
Stock-based compensation expense   9,000       9,830  
Other, net   (213 )     349  
Changes in operating assets and liabilities:      
Accounts and other receivables   (3,035 )     (15,965 )
Prepaid expenses and other assets   1,954       (204 )
Accounts payable, accrued liabilities, and other liabilities   (18,326 )     1,527  
Reserve for veterinary invoices   842       2,407  
Deferred revenue   15,786       15,712  
Net cash provided by operating activities   14,594       15,964  
Investing activities      
Purchases of investment securities   (47,883 )     (40,875 )
Maturities and sales of investment securities   48,878       33,242  
Purchases of property, equipment, and internal-use software   (847 )     (1,928 )
Other   (35 )     588  
Net cash provided by (used in) investing activities   113       (8,973 )
Financing activities      
Repayment of debt financing   (2,500 )     (338 )
Proceeds from exercise of stock options   260       1,024  
Shares withheld to satisfy tax withholding   (496 )     (915 )
Other         (230 )
Net cash used in financing activities   (2,736 )     (459 )
Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash, net   (557 )     (52 )
Net change in cash, cash equivalents, and restricted cash   11,414       6,480  
Cash, cash equivalents, and restricted cash at beginning of period   171,458       199,530  
Cash, cash equivalents, and restricted cash at end of period $ 182,872     $ 206,010  

The following tables set forth our key operating metrics.
                               
  Three Months Ended
March 31,
                       
    2026       2025                          
Total Business:                              
Total pets enrolled (at period end)   1,637,665       1,667,637                          
Subscription Business:                              
Total subscription pets enrolled (at period end)   1,105,783       1,052,845                          
Monthly average revenue per pet $ 85.79     $ 77.53                          
Average pet acquisition cost (PAC) $ 315     $ 267                          
Average monthly retention   98.35 %     98.28 %                        
                               
                               
  Three Months Ended
  Mar. 31, 2026   Dec. 31, 2025   Sep. 30, 2025   Jun. 30, 2025   Mar. 31, 2025   Dec. 31, 2024   Sep. 30, 2024   Jun. 30, 2024
Total Business:                              
Total pets enrolled (at period end)   1,637,665       1,647,565       1,654,414       1,660,455       1,667,637       1,677,570       1,688,903       1,699,643  
Subscription Business:                              
Total subscription pets enrolled (at period end)   1,105,783       1,096,173       1,082,412       1,066,354       1,052,845       1,041,212       1,032,042       1,020,934  
Monthly average revenue per pet $ 85.79     $ 83.56     $ 82.01     $ 79.93     $ 77.53     $ 76.02     $ 74.27     $ 71.72  
Average pet acquisition cost (PAC) $ 315     $ 320     $ 290     $ 276     $ 267     $ 261     $ 243     $ 231  
Average monthly retention   98.35 %     98.34 %     98.33 %     98.29 %     98.28 %     98.25 %     98.29 %     98.34 %

The following table reflects the reconciliation of cash provided by operating activities to free cash flow (in thousands):
       
  Three Months Ended March 31,
    2026       2025  
Net cash provided by operating activities $ 14,594     $ 15,964  
Purchases of property, equipment, and internal-use software   (847 )     (1,928 )
Free cash flow $ 13,747     $ 14,036  

The following table reflects the reconciliation between GAAP and non-GAAP measures (in thousands except percentages):
    Three Months Ended March 31,
      2026       2025  
Veterinary invoice expense   $ 281,436     $ 247,450  
Less:        
Stock-based compensation expense(1)     (552 )     (763 )
Other business cost of paying veterinary invoices(2)     (90,022 )     (79,269 )
Subscription cost of paying veterinary invoices (non-GAAP)   $ 190,862     $ 167,418  
% of subscription revenue     70.8 %     71.8 %
         
Other cost of revenue   $ 41,124     $ 43,422  
Less:        
Stock-based compensation expense(1)     (564 )     (482 )
Other business variable expenses(2)     (16,083 )     (21,736 )
Subscription variable expenses (non-GAAP)   $ 24,477     $ 21,204  
% of subscription revenue     9.1 %     9.1 %
         
Technology and development expense   $ 11,294     $ 8,072  
General and administrative expense     19,102       19,892  
Less:        
Stock-based compensation expense(1)     (6,274 )     (5,396 )
Development expenses(3)     (1,701 )     (1,406 )
Fixed expenses (non-GAAP)   $ 22,421     $ 21,162  
% of total revenue     5.8 %     6.2 %
         
New pet acquisition expense   $ 22,611     $ 20,516  
Less:        
Stock-based compensation expense(1)     (1,425 )     (2,873 )
Other business pet acquisition expense(2)     (26 )     (3 )
Subscription acquisition cost (non-GAAP)   $ 21,160     $ 17,640  
% of subscription revenue     7.9 %     7.6 %
(1)Trupanion employees may elect to take restricted stock units in lieu of cash payment for their bonuses. We account for such expense as stock-based compensation according to GAAP, but we do not include it in any non-GAAP adjustments. Stock-based compensation associated with bonuses was approximately $0.2 million for the three months ended March 31, 2026..
(2)Excludes the portion of stock-based compensation expense attributable to the other business segment
(3)Consists of costs related to product exploration and development that are pre-revenue and historically have been insignificant.

The following table reflects the reconciliation of GAAP measures to non-GAAP measures (in thousands, except percentages):
  Three Months Ended March 31,
    2026       2025  
Operating income (loss) $ 4,776     $ (1,473 )
Non-GAAP expense adjustments      
Acquisition cost   21,186       17,643  
Stock-based compensation expense(1)   8,815       9,514  
Development expenses(2)   1,701       1,406  
Depreciation and amortization   3,706       3,791  
Loss from investment in joint venture         (305 )
Total adjusted operating income (non-GAAP) $ 40,184     $ 31,186  
       
Subscription Business:      
Subscription operating income $ 6,493     $ 1,065  
Non-GAAP expense adjustments      
Acquisition cost   21,160       17,640  
Stock-based compensation expense(1)   6,939       7,772  
Development expenses(2)   1,193       958  
Depreciation and amortization   2,600       2,584  
Subscription adjusted operating income (non-GAAP) $ 38,385     $ 30,019  
       
Other Business:      
Other business operating loss $ (1,717 )   $ (2,233 )
Non-GAAP expense adjustments      
Acquisition cost   26       3  
Stock-based compensation expense(1)   1,876       1,742  
Development expenses(2)   508       448  
Depreciation and amortization   1,106       1,207  
Other business adjusted operating income (non-GAAP) $ 1,799     $ 1,167  
(1)Trupanion employees may elect to take restricted stock units in lieu of cash payment for their bonuses. We account for such expense as stock-based compensation in accordance with GAAP, but we do not include it in any non-GAAP adjustments. Stock-based compensation associated with bonuses was approximately $0.2 million for the three months ended March 31, 2026.
(2)Consists of costs related to product exploration and development that are pre-revenue and historically have been insignificant.

The following tables reflect the reconciliation of GAAP measures to non-GAAP measures (in thousands, except percentages):
    Three Months Ended March 31,
   
      2026       2025  
Subscription revenue   $ 269,454     $ 233,064  
Subscription cost of paying veterinary invoices     190,862       167,418  
Subscription variable expenses     24,477       21,204  
Subscription fixed expenses*     15,730       14,423  
Subscription adjusted operating income (non-GAAP)   $ 38,385     $ 30,019  
         
Other business revenue   $ 114,595     $ 108,911  
Other business cost of paying veterinary invoices     90,022       79,269  
Other business variable expenses     16,083       21,736  
Other business fixed expenses*     6,691       6,739  
Other business adjusted operating income (non-GAAP)   $ 1,799     $ 1,167  
         
Revenue   $ 384,049     $ 341,975  
Cost of paying veterinary invoices     280,884       246,687  
Variable expenses     40,560       42,940  
Fixed expenses*     22,421       21,162  
Total business adjusted operating income (non-GAAP)   $ 40,184     $ 31,186  
         
As a percentage of revenue:   Three Months Ended March 31,
      2026       2025  
Subscription revenue     100.0 %     100.0 %
Subscription cost of paying veterinary invoices     70.8 %     71.8 %
Subscription variable expenses     9.1 %     9.1 %
Subscription fixed expenses*     5.8 %     6.2 %
Subscription adjusted operating income (non-GAAP)     14.2 %     12.9 %
         
Other business revenue     100.0 %     100.0 %
Other business cost of paying veterinary invoices     78.6 %     72.8 %
Other business variable expenses     14.0 %     20.0 %
Other business fixed expenses*     5.8 %     6.2 %
Other business adjusted operating income (non-GAAP)     1.6 %     1.1 %
         
Revenue     100.0 %     100.0 %
Cost of paying veterinary invoices     73.1 %     72.1 %
Variable expenses     10.6 %     12.6 %
Fixed expenses*     5.8 %     6.2 %
Total business adjusted operating income (non-GAAP)     10.5 %     9.1 %
         
*Fixed expenses represent shared services that support both our subscription and other business segments and, as such, are generally allocated to each segment pro-rata based on revenues.
 

Adjusted operating income is a non-GAAP financial measure that adjusts operating income (loss) to remove the effect of acquisition cost, development expenses, non-recurring transaction or restructuring expenses, and gain (loss) from investment in joint venture. Non-cash items, such as goodwill impairment charges, stock-based compensation expense and depreciation and amortization, are also excluded. Acquisition cost, development expenses, gain (loss) from investment in joint venture, stock-based compensation expense, and depreciation and amortization are expected to remain recurring expenses for the foreseeable future, but are excluded from this metric to measure scale in other areas of the business. Management believes acquisition costs primarily represent the cost to acquire new subscribers and are driven by the amount of growth we choose to pursue based primarily on the amount of our adjusted operating income period over period. Accordingly, this measure is not indicative of our core operating income performance. We also exclude development expenses, gain (loss) from investment in joint venture, stock-based compensation expense, and depreciation and amortization because some investors may not view those items as reflective of our core operating income performance.

Management uses adjusted operating income and the margin on adjusted operating income to understand the effects of scale in its non-acquisition cost and development expenses and to plan future advertising expenditures, which are designed to acquire new pets. Management uses this measure as a principal way of understanding the operating performance of its business exclusive of acquisition cost and new product exploration and development initiatives. Management believes disclosure of this metric provides investors with the same data that the Company employs in assessing its overall operations and that disclosure of this measure may provide useful information regarding the efficiency of our utilization of revenues, return on advertising dollars in the form of new subscribers and future use of available cash to support the continued growth of our business.

The following tables reflect the reconciliation of adjusted EBITDA to net income (loss) (in thousands):
                               
  Three Months Ended
March 31,
                       
    2026       2025                          
Net income (loss) $ 4,880     $ (1,483 )                        
Excluding:                              
Stock-based compensation expense(1)   8,815       9,514                          
Depreciation and amortization expense   3,706       3,791                          
Interest income   (2,998 )     (2,835 )                        
Interest expense   1,875       3,211                          
Income tax expense   1,076       39                          
Adjusted EBITDA $ 17,354     $ 12,237                          
                               
  Three Months Ended
  Mar. 31, 2026   Dec. 31, 2025   Sep. 30, 2025   Jun. 30, 2025   Mar. 31, 2025   Dec. 31, 2024   Sep. 30, 2024   Jun. 30, 2024
Net income (loss) $ 4,880     $ 5,630     $ 5,873     $ 9,413     $ (1,483 )   $ 1,656     $ 1,425     $ (5,862 )
Excluding:                              
Stock-based compensation expense(1)   8,815       9,361       9,323       9,268       9,514       8,036       8,127       8,381  
Depreciation and amortization expense   3,706       4,032       4,051       3,962       3,791       3,924       4,381       4,376  
Interest income   (2,998 )     (3,115 )     (3,201 )     (3,105 )     (2,835 )     (2,999 )     (3,232 )     (3,135 )
Interest expense   1,875       4,076       2,790       3,682       3,211       3,427       3,820       3,655  
Income tax (benefit) expense   1,076       663       726       1,133       39       38       39       (44 )
Goodwill impairment charges         1,129                         5,299              
Loss from equity method investment                                       (33 )      
Realized gain on nonmonetary exchange of preferred stock investment                     (7,783 )                        
Adjusted EBITDA $ 17,354     $ 21,776     $ 19,562     $ 16,570     $ 12,237     $ 19,381     $ 14,527     $ 7,371  
(1)Trupanion employees may elect to take restricted stock units in lieu of cash payment for their bonuses. We account for such expense as stock-based compensation according to GAAP, but we do not include it in any non-GAAP adjustments. Stock-based compensation associated with bonuses was approximately $0.2 million for the three months ended March 31, 2026.
 


Contacts

:

Investors:

Laura Bainbridge, Senior Vice President, Corporate Communications
Gil Melchior, Director, Investor Relations
[email protected]



Universal Display Corporation Announces First Quarter 2026 Financial Results

Universal Display Corporation Announces First Quarter 2026 Financial Results

EWING, N.J.–(BUSINESS WIRE)–Universal Display Corporation (Nasdaq: OLED), a global leader in energy-efficient OLED technologies and materials, today reported financial results for the first quarter ended March 31, 2026.

“We continue to see the OLED market as a compelling long-term growth opportunity, supported by expanding adoption, evolving architectures, and continued industry investment,” said Brian Millard, Chief Financial Officer of Universal Display Corporation. “While near-term market conditions have become more measured, we remain focused on execution and long-term value creation. That focus is supported by our deep and long-standing customer partnerships and continued innovation across our materials and technology platforms, which positions us well as the industry enters its next phase of growth, including Gen 8.6 capacity additions in Korea and China expected to come online this year. As this growth unfolds, OLED performance requirements continue to rise and architectures evolve, further increasing the importance of materials innovation. We continue to invest in our technology leadership, while leveraging our strong balance sheet and cash flow generation to support future growth and return capital to shareholders in a disciplined manner.”

Financial Highlights for the First Quarter of 2026

  • Total revenue in the first quarter of 2026 was $142.2 million as compared to $166.3 million in the first quarter of 2025.

  • Revenue from material sales was $83.7 million in the first quarter of 2026 as compared to $86.2 million in the first quarter of 2025. The decrease was primarily due to changes in customer mix and lower unit material volume.

  • Revenue from royalty and license fees was $54.2 million in the first quarter of 2026 as compared to $73.6 million in the first quarter of 2025. The decrease was primarily the result of changes in customer mix and lower unit material volume. While customer mix can vary quarter to quarter, we expect the customer mix in subsequent periods of 2026 to have a more favorable impact on royalty and license fees as compared to the first quarter of the year.

  • Cost of material sales was $33.0 million in the first quarter of 2026 as compared to $33.9 million in the first quarter of 2025.

  • Total gross margin was 75% in the first quarter of 2026 as compared to 77% in the first quarter of 2025.

  • Operating income was $42.8 million in the first quarter of 2026 as compared to $69.7 million in the first quarter of 2025.

  • The effective income tax rate was 20.7% in the first quarter of 2026 as compared to 19.6% in the first quarter of 2025.

  • Net income was $35.9 million or $0.76 per diluted share in the first quarter of 2026 as compared to $64.4 million or $1.35 per diluted share in the first quarter of 2025.

Revenue Comparison

($ in thousands)

 

Three Months Ended March 31,

 

 

2026

 

2025

Material sales

 

$

83,749

 

 

$

86,155

 

Royalty and license fees

 

 

54,210

 

 

 

73,569

 

Contract research services

 

 

4,252

 

 

 

6,553

 

Total revenue

 

$

142,211

 

 

$

166,277

 

Cost of Materials Comparison

($ in thousands)

 

Three Months Ended March 31,

 

 

2026

 

2025

Material sales

 

$

83,749

 

 

$

86,155

 

Cost of material sales

 

 

33,017

 

 

 

33,949

 

Gross margin on material sales

 

 

50,732

 

 

 

52,206

 

Gross margin as a % of material sales

 

 

61

%

 

 

61

%

Revised 2026 Guidance

The Company now believes that its 2026 revenue will be in the range of $630 million to $670 million, down from prior guidance of $650 million to $700 million. The OLED industry remains at a stage where many variables can have a material impact on results, and the Company thus caveats its financial guidance accordingly.

Dividend

The Company also announced a second quarter 2026 cash dividend of $0.50 per share on the Company’s common stock. The cash dividend is payable on June 30, 2026 to all shareholders of record as of the close of business on June 16, 2026.

Share Repurchases

The Company repurchased 632,673 shares of common stock for $66.4 million during the three months ended March 31, 2026. During the same period, and inclusive of such purchases, the Company completed the share repurchase program authorized in April 2025, repurchasing a total of 923,883 shares of its common stock for an aggregate purchase price of $100 million.

On April 28, 2026, the Company’s Board of Directors authorized management to repurchase up to an additional $400 million of the Company’s common stock.

Conference Call Information

In conjunction with this release, Universal Display will host a conference call on Thursday, April 30, 2026 at 5:00 p.m. Eastern Time. The live webcast of the conference call can be accessed under the events page of the Company’s Investor Relations website at ir.oled.com. Those wishing to participate in the live call should dial 1-877-524-8416 (toll-free) or 1-412-902-1028. Please dial in 5-10 minutes prior to the scheduled conference call time. An online archive of the webcast will be available within two hours of the conclusion of the call.

About Universal Display Corporation

Universal Display Corporation (Nasdaq: OLED) is a leader in the research, development and commercialization of organic light emitting diode (OLED) technologies and materials for use in display and solid-state lighting applications. Founded in 1994 and with subsidiaries and offices around the world, the Company currently owns, exclusively licenses or has the sole right to sublicense more than 7,000 patents issued and pending worldwide. Universal Display licenses its proprietary technologies, including its breakthrough high-efficiency UniversalPHOLED® phosphorescent OLED technology that can enable the development of energy-efficient and eco-friendly displays and solid-state lighting. The Company also develops and offers high-quality, state-of-the-art UniversalPHOLED materials that are recognized as key ingredients in the fabrication of OLEDs with peak performance. In addition, Universal Display delivers innovative and customized solutions to its clients and partners through technology transfer, collaborative technology development and on-site training. To learn more about Universal Display Corporation, please visit https://oled.com/.

Universal Display Corporation and the Universal Display Corporation logo are trademarks or registered trademarks of Universal Display Corporation. All other Company, brand or product names may be trademarks or registered trademarks.

All statements in this document that are not historical, such as those relating to the projected adoption, development and advancement of the Company’s technologies, and the Company’s expected results, as well as the growth of the OLED market and the Company’s opportunities in that market, are forward-looking financial statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on any forward-looking statements in this document, as they reflect Universal Display Corporation’s current views with respect to future events and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated. These risks and uncertainties are discussed in greater detail in Universal Display Corporation’s periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission, including, in particular, the section entitled “Risk Factors” in Universal Display Corporation’s Annual Report on Form 10-K for the year ended December 31, 2025. Universal Display Corporation disclaims any obligation to update any forward-looking statement contained in this document.

Follow Universal Display Corporation

X

Facebook

YouTube

(OLED-C)

UNIVERSAL DISPLAY CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(in thousands, except share and per share data)

 

 

 

March 31, 2026

 

December 31, 2025

ASSETS

 

 

 

 

 

 

CURRENT ASSETS:

 

 

 

 

 

 

Cash and cash equivalents

 

$

159,352

 

 

$

138,353

 

Short-term investments

 

 

357,056

 

 

 

464,004

 

Accounts receivable

 

 

93,629

 

 

 

119,953

 

Inventory

 

 

248,213

 

 

 

240,912

 

Other current assets

 

 

74,028

 

 

 

123,836

 

Total current assets

 

 

932,278

 

 

 

1,087,058

 

PROPERTY AND EQUIPMENT, net of accumulated depreciation of $196,869 and $189,326

 

 

213,146

 

 

 

214,947

 

ACQUIRED TECHNOLOGY, net of accumulated amortization of $225,627 and $220,392

 

 

101,548

 

 

 

56,783

 

OTHER INTANGIBLE ASSETS, net of accumulated amortization of $13,622 and $13,269

 

 

3,666

 

 

 

4,019

 

GOODWILL

 

 

15,535

 

 

 

15,535

 

INVESTMENTS

 

 

419,673

 

 

 

377,034

 

DEFERRED INCOME TAXES

 

 

79,455

 

 

 

79,454

 

OTHER ASSETS

 

 

129,415

 

 

 

128,932

 

TOTAL ASSETS

 

$

1,894,716

 

 

$

1,963,762

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

 

 

CURRENT LIABILITIES:

 

 

 

 

 

 

Accounts payable

 

$

17,037

 

 

$

23,344

 

Accrued expenses

 

 

40,389

 

 

 

52,564

 

Deferred revenue

 

 

21,038

 

 

 

21,011

 

Other current liabilities

 

 

19,300

 

 

 

11,094

 

Total current liabilities

 

 

97,764

 

 

 

108,013

 

DEFERRED REVENUE

 

 

1,728

 

 

 

1,943

 

RETIREMENT PLAN BENEFIT LIABILITY

 

 

56,911

 

 

 

56,541

 

OTHER LIABILITIES

 

 

34,333

 

 

 

36,246

 

Total liabilities

 

 

190,736

 

 

 

202,743

 

SHAREHOLDERS’ EQUITY:

 

 

 

 

 

 

Preferred Stock, par value $0.01 per share, 5,000,000 shares authorized, 200,000 shares of Series A Nonconvertible Preferred Stock issued and outstanding (liquidation value of $7.50 per share or $1,500)

 

 

2

 

 

 

2

 

Common Stock, par value $0.01 per share, 200,000,000 shares authorized, 49,039,974 and 48,916,606 shares issued, and 46,750,443 and 47,259,748 shares outstanding, at March 31, 2026 and December 31, 2025, respectively

 

 

490

 

 

 

489

 

Additional paid-in capital

 

 

745,385

 

 

 

744,692

 

Retained earnings

 

 

1,102,489

 

 

 

1,090,479

 

Accumulated other comprehensive (loss) income

 

 

(2,567

)

 

 

781

 

Treasury stock, at cost (2,289,531 and 1,656,858 shares at March 31, 2026 and December 31, 2025)

 

 

(141,819

)

 

 

(75,424

)

Total shareholders’ equity

 

 

1,703,980

 

 

 

1,761,019

 

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

 

$

1,894,716

 

 

$

1,963,762

 

UNIVERSAL DISPLAY CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

(in thousands, except share and per share data)

 

 

 

Three Months Ended March 31,

 

 

2026

 

2025

REVENUE:

 

 

 

 

 

 

Material sales

 

$

83,749

 

 

$

86,155

 

Royalty and license fees

 

 

54,210

 

 

 

73,569

 

Contract research services

 

 

4,252

 

 

 

6,553

 

Total revenue

 

 

142,211

 

 

 

166,277

 

COST OF SALES

 

 

36,121

 

 

 

38,134

 

Gross margin

 

 

106,090

 

 

 

128,143

 

OPERATING EXPENSES:

 

 

 

 

 

 

Research and development

 

 

35,246

 

 

 

34,900

 

Selling, general and administrative

 

 

20,032

 

 

 

17,014

 

Amortization of acquired technology and other intangible assets

 

 

5,588

 

 

 

4,545

 

Patent costs

 

 

2,369

 

 

 

1,906

 

Royalty and license expense

 

 

104

 

 

 

114

 

Total operating expenses

 

 

63,339

 

 

 

58,479

 

OPERATING INCOME

 

 

42,751

 

 

 

69,664

 

Interest income, net

 

 

8,715

 

 

 

10,074

 

Other (loss) income, net

 

 

(6,173

)

 

 

378

 

Interest and other income, net

 

 

2,542

 

 

 

10,452

 

INCOME BEFORE INCOME TAXES

 

 

45,293

 

 

 

80,116

 

INCOME TAX EXPENSE

 

 

(9,397

)

 

 

(15,672

)

NET INCOME

 

$

35,896

 

 

$

64,444

 

NET INCOME PER COMMON SHARE:

 

 

 

 

 

 

BASIC

 

$

0.76

 

 

$

1.35

 

DILUTED

 

$

0.76

 

 

$

1.35

 

WEIGHTED AVERAGE SHARES USED IN COMPUTING NET INCOME PER COMMON SHARE:

 

 

 

 

 

 

BASIC

 

 

47,078,940

 

 

 

47,567,295

 

DILUTED

 

 

47,205,952

 

 

 

47,689,657

 

CASH DIVIDENDS DECLARED PER COMMON SHARE

 

$

0.50

 

 

$

0.45

 

UNIVERSAL DISPLAY CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(in thousands)

 

 

 

Three Months Ended March 31,

 

 

2026

 

2025

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

Net income

 

$

35,896

 

 

$

64,444

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

Depreciation

 

 

7,563

 

 

 

6,548

 

Amortization of intangibles

 

 

5,588

 

 

 

4,545

 

Investment losses (gains), net

 

 

2,086

 

 

 

(1,471

)

Impairment of minority investments

 

 

415

 

 

 

 

Stock-based compensation

 

 

7,554

 

 

 

7,076

 

Deferred income tax expense (benefit)

 

 

3

 

 

 

(3,091

)

Retirement plan expense, net of benefit payments

 

 

375

 

 

 

423

 

Decrease (increase) in assets:

 

 

 

 

 

 

Accounts receivable

 

 

26,324

 

 

 

(25,915

)

Inventory

 

 

(7,301

)

 

 

(14,460

)

Other current assets

 

 

39,808

 

 

 

400

 

Other assets

 

 

(483

)

 

 

(2,568

)

Increase (decrease) in liabilities:

 

 

 

 

 

 

Accounts payable and accrued expenses

 

 

(15,362

)

 

 

(13,408

)

Other current liabilities

 

 

8,291

 

 

 

16,867

 

Deferred revenue

 

 

(188

)

 

 

(8,491

)

Other liabilities

 

 

(1,693

)

 

 

(337

)

Net cash provided by operating activities

 

 

108,876

 

 

 

30,562

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

Purchases of property and equipment

 

 

(8,605

)

 

 

(13,059

)

Purchase of intangibles

 

 

(40,000

)

 

 

 

Purchases of investments

 

 

(116,009

)

 

 

(38,772

)

Proceeds from sale and maturity of investments

 

 

174,483

 

 

 

110,000

 

Net cash provided by investing activities

 

 

9,869

 

 

 

58,169

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

Proceeds from issuance of common stock

 

 

578

 

 

 

579

 

Repurchases of common stock

 

 

(67,119

)

 

 

 

Payment of withholding taxes related to stock-based compensation to employees

 

 

(7,738

)

 

 

(9,398

)

Cash dividends paid

 

 

(23,467

)

 

 

(21,419

)

Net cash used in financing activities

 

 

(97,746

)

 

 

(30,238

)

INCREASE IN CASH AND CASH EQUIVALENTS

 

 

20,999

 

 

 

58,493

 

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD

 

 

138,353

 

 

 

98,980

 

CASH AND CASH EQUIVALENTS, END OF PERIOD

 

$

159,352

 

 

$

157,473

 

SUPPLEMENTAL DISCLOSURES:

 

 

 

 

 

 

Unrealized (loss) gain on available-for-sale securities

 

$

(3,334

)

 

$

1,320

 

Common stock issued to Board of Directors and Scientific Advisory Board that was earned and accrued for in a previous period

 

 

300

 

 

 

300

 

Accrued dividends included in other current liabilities and other liabilities

 

 

419

 

 

 

124

 

Net change in accounts payable and accrued expenses related to purchases of property and equipment

 

 

2,843

 

 

 

5,487

 

Cash paid for income taxes, net of refunds

 

 

38,376

 

 

 

2,266

 

 

Universal Display Contact:

Darice Liu

[email protected]

[email protected]

+1 609-964-5123

KEYWORDS: New Jersey United States North America

INDUSTRY KEYWORDS: Research Professional Services Hardware Consumer Electronics Alternative Energy Energy Technology Semiconductor Science Nanotechnology Audio/Video Finance

MEDIA:

Logo
Logo

Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain

Contineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain

The trial achieved its primary endpoint demonstrating favorable safety and tolerability

Encouraging trends observed across multiple exploratory efficacy endpoints including improvements in measures of pain and other functional patient-reported outcomes

Results support further evaluation of PIPE-791 for the potential treatment of chronic pain

SAN DIEGO–(BUSINESS WIRE)–
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported positive topline data from its exploratory Phase 1b trial of PIPE-791, a potentially best-in-class selective antagonist of the lysophosphatidic acid 1 (LPA1) receptor, for the non-opioid treatment of chronic osteoarthritis pain (COAP) or chronic low back pain (CLBP).

“These results demonstrate that PIPE-791, administered as a once-daily 10mg oral dose, was well tolerated in the largest patient population and longest treatment duration studied to date, reinforcing our confidence in its profile and its potential relevance to the PROPEL-IPF trial,” said Timothy Watkins, M.D., M.Sc., Chief Medical Officer and Head of Development, Contineum Therapeutics. “We are pleased with these results, which showed consistent trends toward improvement across multiple exploratory efficacy endpoints evaluating chronic pain that, in general, numerically outperformed placebo. These endpoints included measures of average daily pain, worst daily pain and the proportion of patients demonstrating a 30% or greater reduction in pain from baseline. We believe these findings, particularly the COAP data, provide evidence of preliminary efficacy that support further evaluation of PIPE-791 for the potential treatment of chronic pain, and we are contemplating next steps for further clinical development.”

Clinical Trial Overview

The randomized, double-blind, placebo-controlled, 4-week, crossover trial enrolled 43 patients (23 COAP and 20 CLBP). The trial design incorporated a washout period for patients prior to the first 4-week treatment period (TP1), after which patients crossed over immediately into a second 4-week treatment period (TP2) without an intervening PIPE-791 washout. PIPE-791 was administered orally at 10mg once-daily. More information on this trial can be found at https://clinicaltrials.gov (NCT06810245).

Safety and Tolerability

The trial met its primary objective of assessing safety and tolerability, demonstrating an adverse event (AE) profile generally consistent with previous PIPE-791 clinical trials. Most treatment-emergent adverse events (TEAEs) were mild to moderate, with no serious AEs reported. The most common TEAEs were headache (n=3) and fatigue (n=2). No clinically meaningful changes in mean systolic or diastolic blood pressure or clinically-relevant orthostatic events were observed.

Exploratory Efficacy Results

Pain intensity was assessed using the 11-point Pain-Intensity Numerical Rating Scale (PI-NRS). The PI-NRS was analyzed as the change from baseline in weekly average of average daily pain. Patients treated with PIPE-791 generally demonstrated improvements from baseline in pain that were numerically greater than the placebo arm. Similar trends were observed when PI-NRS was evaluated as the weekly average of the worst level of daily pain.

Weekly Average of Average Daily PI-NRS Scores and Changes to End of Treatment

 

COAP

CLBP

Treatment Period 1

PIPE-791 (N=11)

Placebo (N=11)

PIPE-791 (N=10)

Placebo (N=10)

Baseline Weekly

Average PI-NRS*

5.58 (1.21)

6.23 (1.43)

5.60 (1.27)

5.57 (1.50)

Change from Baseline

(95% CI)

-1.60

(-2.49, -0.72)

-1.27

(-2.15, -0.39)

-1.33

(-1.83, -0.84)

-0.55

(-1.33, 0.22)

Treatment Period 2

PIPE-791 (N=11)

Placebo (N=10)

PIPE-791 (N=9)

Placebo (N=10)

Baseline Weekly

Average PI-NRS*

4.96 (2.21)

3.56 (1.45)

4.72 (1.89)

4.75 (1.81)

Change from Baseline

(95% CI)

-1.42

(-2.28, -0.56)

-0.74

(-1.83, 0.35)

0.13

(-0.68, 0.94)

-0.55

(-2.38, 1.29)

* Reported as Mean (standard deviation – SD) of the daily average PI-NRS scores for the 7 days preceding randomization (Treatment Period 1) or Week 5 (Treatment Period 2), respectively.

† Reported as the Mean change from Baseline in the weekly average of the daily average PI-NRS scores, 95% Confidence Interval (CI), to the end of Treatment Period 1 (Week 4) or the end of Treatment Period 2 (Week 8), respectively.

In addition to the average measures of PI-NRS, exploratory efficacy endpoints included an assessment of clinical responders (30% ≥ reduction from baseline in PI-NRS) and the Modified Knee Injury and Osteoarthritis Outcome Scale (KOOS). Results from these exploratory measures further supported the positive PI-NRS findings.

Dr. Robert H. Dworkin, Professor of Anesthesiology and Perioperative Medicine and of Neurology at University of Rochester Medicine, added, “Chronic pain remains a very significant unmet medical need, particularly for patients seeking effective and safe non-opioid treatment options. The early signals observed with PIPE-791, including improvements in pain measures and responder rates, are encouraging. The novel LPA1 activity targets underlying mechanisms of pain. These data provide compelling support for further clinical investigation.”

PIPE-791 For the Treatment of Chronic Pain

Chronic pain is often associated with neuropathic symptoms caused by aberrant signaling in the central nervous system (CNS). LPA1 activation has been shown preclinically to contribute to persistent hypersensitivity through demyelination of nerve fibers, increased neuronal excitability and neuroinflammation. By selectively blocking LPA1, PIPE-791 has the potential to modulate the maladaptive changes in the CNS and reduce pain.

About Contineum Therapeutics

Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis and chronic pain. PIPE-307 is a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis and major depressive disorder. For more information, please visit www.contineum-tx.com.

Forward-Looking Statements

Certain statements contained in this press release, other than historical information, constitute forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include, but are not limited to, implied or express statements regarding the pharmacological properties, safety, tolerability, clinical response and efficacy, and therapeutic potential of PIPE-791 for the treatment of chronic pain; the dosing requirements of PIPE-791 based on the Company’s Phase 1b clinical trial; or the potential of the data from the Company’s Phase 1b clinical trial to predict future clinical outcomes or results; the Company’s business strategies and plans; and the quotations of the Company’s management, scientific advisors, or other third parties including outside experts. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond the Company’s control and may cause its actual results, events, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties, include, but are not limited to, the following: the Company is heavily dependent on the success of PIPE-791 and PIPE-307, both of which are in the early stages of clinical development, and neither of these drug candidates may progress through clinical development or receive regulatory approval; the results of preclinical studies and clinical trials, including those conducted by third parties, may not be predictive of future results and unexpected adverse side effects or inadequate efficacy of the Company’s drug candidates may limit their development, regulatory approval and/or commercialization; the timing and outcome of research, development and regulatory review is uncertain; the FDA or comparable foreign regulatory authorities may disagree as to the design or implementation of our proposed clinical trials; clinical trials and preclinical studies may not proceed at the time or in the manner expected, or at all; the Company may use its capital resources sooner than expected and they may be insufficient to allow the Company to achieve its anticipated milestones; the potential for the Company’s programs and prospects to be negatively impacted by developments relating to the Company’s competitors, including the results of studies or regulatory determinations relating to the Company’s competitors; the Company’s reliance, pursuant to a global license and development agreement, upon Janssen Pharmaceutica NV, a Johnson & Johnson company, to develop, in its sole discretion, PIPE-307 for relapsing-remitting multiple sclerosis, major depressive disorder or for any other indication; the Company has incurred significant operating expenses since inception and it expects that its operating expenses will continue to significantly increase for the foreseeable future; the Company’s ability to operate in a competitive industry and compete successfully against competitors that have greater resources than the Company does; the Company may be unable to obtain, maintain and enforce intellectual property protection for its technology and drug candidates; and unstable market and economic conditions and military conflict may adversely affect the Company’s business and financial condition and the broader economy and biotechnology industry. Additional risks and uncertainties that could affect the Company’s business, operations and results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s periodic filings and in other filings that the Company makes with the Securities and Exchange Commission (SEC) from time to time, which are available on the Company’s website at www.contineum-tx.com under the Investor section and on the SEC’s website at www.sec.gov. Accordingly, readers should not rely upon forward-looking statements as predictions of future events. Except as required by applicable law, the Company undertakes no obligation to update publicly or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Steve Kunszabo

Contineum Therapeutics

Senior Director, Investor Relations & Corporate Communications

858-649-1158

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Biotechnology Neurology Health Pharmaceutical Clinical Trials

MEDIA:

Logo
Logo

Zeta Global Revenue Growth Accelerates to 50% and “Beats and Raises” for Its 19th Consecutive Quarter on the Heels of the Athena by Zeta™ Launch

Zeta Global Revenue Growth Accelerates to 50% and “Beats and Raises” for Its 19th Consecutive Quarter on the Heels of the Athena by Zeta™ Launch

  • Delivered revenue of $396 million for the first quarter, an increase of 50% Y/Y, exceeding midpoint of guidance by $26 million.
  • Grew Super-Scaled Customer count to 189, an increase of 19% Y/Y and Super-Scaled customer ARPU grew to $1.7 million, up 21% Y/Y.
  • Increasing full year 2026 revenue guidance by $30 million to $1,785 million at the midpoint, up from prior guidance of $1,755 million reflecting Y/Y growth of 37%.
  • Athena drove greater than 7X more agent interactions and accounted for over 60% of AI platform usage in its first week of general availability.

NEW YORK–(BUSINESS WIRE)–
Zeta Global (NYSE: ZETA), the AI Marketing Cloud, today announced financial results for the first quarter ended March 31, 2026.

“Accelerating revenue growth to 50% and achieving the Rule of 67 in the first quarter is further evidence we are winning in this environment, powered by the system we have built: proprietary data that improves with every interaction, intelligence that compounds with every decision, and a platform with AI at its core that allows customers to consolidate vendors into a single, unified operating model. This results in an average 600% return on marketing spend for our customers,” said David A. Steinberg, Co-Founder, Chairman, and CEO of Zeta. “Athena accelerates that system as the core operating system that brings AI directly into workflows and removes the barrier to enterprise-wide adoption. Zeta is the disruptor in the AI driven replacement cycle.”

“Nineteen consecutive beat-and-raise quarters is not just consistency — it is evidence of sustained demand in a market consolidating around platforms that can deliver measurable outcomes at scale and meet the needs of customers in an AI-native world,” said Chris Greiner, Zeta’s CFO. “And that strength is reflected in our outlook — after raising the midpoint of our 2026 revenue guidance last quarter by $25 million, we are again raising it by $30 million, representing growth of 37%.”

Increasing 2026 Guidance*

Second Quarter 2026

  • Increasing revenue guidance to a range of $419 million to $422 million, up $4 million at the midpoint from the prior guidance of $416 million. The revised guidance represents a year-over-year growth rate of 36% to 37%, and 20% to 21% when excluding political candidate and Marigold’s Enterprise Business revenue.

  • Increasing adjusted EBITDA guidance to a range of $86.2 million to $86.9 million, up $1.7 million at the midpoint from the prior guidance of $84.9 million. The revised guidance represents a year-over-year growth rate of 47% to 48% and an adjusted EBITDA margin of 20.4% to 20.8%.

Full Year 2026

  • Increasing revenue guidance to a range of $1,779 million to $1,792 million, up $30 million at the midpoint from the prior guidance of $1,755 million. Revised guidance represents a year-over-year growth rate of 36% to 37%, and 22% to 23% when excluding political candidate and Marigold’s Enterprise Business revenue.

  • Increasing adjusted EBITDA guidance to a range of $396.2 million to $398.4 million, up $6.3 million at the midpoint from the prior guidance of $391.0 million. Revised guidance represents a year-over-year growth rate of 42% to 43% and an adjusted EBITDA margin of 22.1% to 22.4%.

  • Increasing free cash flow guidance to a range of $234.5 million to $235.5 million, up $3.8 million at the midpoint from the prior guidance of $231.2 million. Revised guidance represents a year-over-year growth rate of 42% to 43% and a free cash flow margin of 13.1% to 13.2%.

  • Guiding to positive GAAP Net Income for the full year 2026.

* This press release does not include a reconciliation of forward-looking adjusted EBITDA, adjusted EBITDA margin, free cash flow, and free cash flow margin to forward-looking GAAP net income (loss), net income (loss) margin, net cash provided by operating activities, or net cash provided by operating activities margin, respectively, because the Company is unable, without making unreasonable efforts, to provide a meaningful or reasonably accurate calculation or estimation of certain reconciling items which could be significant to the Company’s results.

Investor Conference Call and Webcast

Zeta will host a conference call today, Thursday, April 30, 2026, at 4:30 p.m. Eastern Time to discuss financial results for the first quarter of 2026. A supplemental earnings presentation and a live webcast of the conference call can be accessed from the Company’s investor relations website (https://investors.zetaglobal.com/) where they will remain available for one year.

About Zeta

Zeta Global (NYSE: ZETA) is the AI Marketing Cloud that leverages advanced artificial intelligence (AI) and trillions of consumer signals to make it easier for marketers to acquire, grow, and retain customers more efficiently. Through the Zeta Marketing Platform (ZMP), our vision is to make sophisticated marketing simple by unifying identity, intelligence, and omnichannel activation into a single platform – powered by one of the industry’s largest proprietary databases and AI. Our enterprise customers across multiple verticals are empowered to personalize experiences with consumers at an individual level across every channel, delivering better results for marketing programs. Zeta was founded in 2007 by David A. Steinberg and John Sculley and is headquartered in New York City with offices around the world. To learn more, go to www.zetaglobal.com.

Forward-Looking Statements

This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Any statements made in this press release or during the earnings call that are not statements of historical fact, including statements about our second quarter 2026 guidance, full year 2026 guidance, the Zeta 2028 targets, the expected benefits, adoption, and impact of Athena, expectations regarding the contribution of Marigold’s Enterprise Business, anticipated market share growth, the impacts of our prior investments on accelerating the timing of the marketing cloud replacement cycle, our products capabilities to provide strong investment returns to our customers, our strong competitive position, expansion of existing customers, the capabilities of AI and Zeta’s platform, the predictability and profitability of our growth, and the growth and expansion of AI and the Zeta Marketing Platform, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning our anticipated future financial performance, our market opportunities and our expectations regarding our business plan and strategies. These statements often include words such as “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast,” “outlook,” “guidance” and other similar expressions. We base these forward-looking statements on our current expectations, plans and assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at such time. Although we believe that these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our business, results of operations and financial condition and could cause actual results to differ materially from those expressed in the forward-looking statements. These statements are not guarantees of future performance or results.

The forward-looking statements are subject to and involve risks, uncertainties and assumptions, and you should not place undue reliance on these forward-looking statements. Factors that may materially affect such forward-looking statements include, but are not limited to: global supply chain disruptions; macroeconomic and industry trends and adverse developments in the debt, consumer credit and financial services markets and other macroeconomic factors beyond Zeta’s control; increases in our borrowing costs as a result of changes in interest rates and other factors; the impact of inflation, tariffs and changes in global trade policies on us and on our customers; potential fluctuations in our operating results, which could make our future operating results difficult to predict; underlying circumstances, including cash flows, cash position, financial performance, market conditions and potential acquisitions; prevailing stock prices, general economic and market conditions; the impact of future pandemics, epidemics and other health crises on the global economy, our customers, employees and business; domestic and international political and geopolitical conditions or uncertainty, including political or civil unrest or changes in trade policy; our ability to innovate and make the right investment decisions in our product offerings and platform; the impact of new generative AI capabilities and the proliferation of AI on our business; our ability to attract and retain customers, including our super-scaled customers; our ability to manage our growth effectively; our ability to identify and integrate acquisitions or strategic investments; our ability to collect and use data online; the standards that private entities and inbox service providers adopt in the future to regulate the use and delivery of email may interfere with the effectiveness of our platform and our ability to conduct business; a significant inadvertent disclosure or breach of confidential and/or personal information we process, or a security breach of our or our customers’, suppliers’ or other partners’ computer systems; and any disruption to our third-party data centers, systems and technologies. These cautionary statements should not be construed by you to be exhaustive and the forward-looking statements are made only as of the date of this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

The second quarter and full year 2026 guidance provided herein and the Zeta 2028 targets are based on Zeta’s current estimates and assumptions and are not a guarantee of future performance. The guidance and the Zeta 2028 targets provided are subject to significant risks and uncertainties, including the risk factors discussed in the Company’s reports on file with the Securities and Exchange Commission (“SEC”), that could cause actual results to differ materially. There can be no assurance that the Company will achieve the results expressed by this guidance or the targets.

Availability of Information on Zeta’s Website and Social Media Profiles

Investors and others should note that Zeta routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the Zeta investor relations website at https://investors.zetaglobal.com (“Investors Website”). We also intend to use the social media profiles listed below as a means of disclosing information about us to our customers, investors and the public. While not all of the information that the Company posts to the Investors Website or to social media profiles is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media, and others interested in Zeta to review the information that it shares on the Investors Website and to regularly follow our social media profile links located at the bottom of the page on www.zetaglobal.com. Users may automatically receive email alerts and other information about Zeta when enrolling an email address by visiting “Investor Email Alerts” in the “Resources” section of the Investors Website.

Social Media Profiles:

www.x.com/zetaglobal

www.facebook.com/zetaglobal/

www.linkedin.com/company/zetaglobal

www.instagram.com/zetaglobal/

www.youtube.com/@zetaglobal

The Following Definitions Apply to the Terms Used Throughout this Release, the Supplemental Earnings Presentation and Investor Conference Call

  • Direct Platform and Integrated Platform: When the Company generates revenues entirely through the Company platform, the Company considers it direct platform revenue. When the Company generates revenue by leveraging its platform’s integration with third parties, it is considered integrated platform revenue.
  • Cost of revenues (excluding depreciation and amortization): Cost of revenues excludes depreciation and amortization and consists primarily of media and marketing costs and certain employee-related costs. Media and marketing costs consist primarily of fees paid to third-party publishers, media owners or managers, and strategic partners that are directly related to revenue-generating events. We pay these third-party publishers, media owners or managers and strategic partners on revenue-share, a cost-per-lead, cost-per-click, or cost-per-thousand-impressions basis. Expenses related to “internet traffic” associated with the viewing of available impressions or queries per second and costs of providing support to our customers are also included in the cost of revenues (excluding depreciation and amortization). Employee-related costs included in cost of revenues (excluding depreciation and amortization) include salaries, bonuses, commissions, stock-based compensation and employee benefit costs primarily related to individuals directly associated with providing services to our customers. Our cost of revenues (excluding depreciation and amortization) is dependent on the revenue mix and therefore can slightly increase or decrease in the future as a percentage of revenue over the long term.
  • Super-Scaled Customers: We define super-scaled customers, which is a subset of Scaled Customers, as customers from which we generated at least $1,000,000 in revenue on a trailing twelve-month basis. We calculate the number of super-scaled customers at the end of each quarter and on an annual basis as the number of customers billed during each applicable period. We believe the super-scaled customers measure is both an important contributor to our revenue growth and an indicator to investors of our measurable success.
  • Super-Scaled Customer ARPU: We calculate the super-scaled customer ARPU as revenue for the corresponding period divided by the number of super-scaled customers at the end of that period. We believe that super-scaled customer ARPU is useful for investors because it is an indicator of our ability to increase revenue and scale our business.
  • Zeta 2028: Zeta 2028 is the Company’s next medium-term plan with targets for business, product, and industry leadership.
  • Rule of 67: We define the Rule of 67 as the combination of revenue growth percentage plus adjusted EBITDA margin percentage adding up to 67 or more.

Non-GAAP Measures

In order to assist readers of our consolidated financial statements in understanding the core operating results that our management uses to evaluate the business and for financial planning purposes, we describe our non-GAAP measures below. We believe these non-GAAP measures are useful to investors in evaluating our performance by providing an additional tool for investors to use in comparing our financial performance over multiple periods.

  • Adjusted EBITDA is a non-GAAP financial measure defined as net income / (loss) adjusted for interest expenses, net, depreciation and amortization, stock-based compensation, income tax (benefit) / provision, acquisition-related expenses, restructuring expenses, change in fair value of warrants and derivative liabilities, certain dispute settlement expenses, gain on extinguishment of debt, certain non-recurring capital raise related (including initial public offering (“IPO”)) expenses, including the payroll taxes related to vesting of restricted stock and restricted stock units upon the completion of the IPO, and other (income) / expenses. Acquisition-related expenses and restructuring expenses primarily consist of professional services fees, severance and other employee-related costs, which may vary from period to period depending on the timing of our acquisitions and restructuring activities and may distort the comparability of the results of operations. Change in fair value of warrants and derivative liabilities is a non-cash expense related to periodically recording “mark-to-market” changes in the valuation of derivatives and warrants. Other (income) / expenses consists of non-cash expenses such as changes in fair value of acquisition-related liabilities, gains and losses onextinguishment of acquisition-related liabilities,gains and losses on sales of assets and foreign exchange gains and losses. In particular, we believe that the exclusion of stock-based compensation, certain dispute settlement expenses and non-recurring capital raise related (including IPO) expenses that are not related to our core operations provides measures for period-to-period comparisons of our business and provides additional insight into our core controllable costs. We exclude these charges because these expenses are not reflective of ongoing business and operating results.
  • Adjusted EBITDA margin is a non-GAAP financial measure defined as adjusted EBITDA divided by the total revenues for the same period.
  • Free cash flow is a non-GAAP financial measure defined as cash from operating activities, less capital expenditures and website and software development costs, adjusted for the effect of exchange rates on cash and cash equivalents.
  • Free cash flow margin is a non-GAAP financial measure defined as free cash flow divided by revenue for the same period.

Adjusted EBITDA, adjusted EBITDA margin, free cash flow, and free cash flow margin provide us with useful measures for period-to-period comparisons of our business as well as comparison to our peers. We believe that these non-GAAP financial measures are useful to investors in analyzing our financial and operational performance. Nevertheless, our use of adjusted EBITDA, adjusted EBITDA margin, free cash flow, and free cash flow margin has limitations as an analytical tool, and you should not consider these measures in isolation or as a substitute for analysis of our financial results as reported under GAAP. Other companies may calculate similarly-titled non-GAAP financial measures differently than us, thereby limiting the usefulness of these non-GAAP financial measures as a comparative tool. Because of these and other limitations, you should consider our non-GAAP measures only as supplemental to other GAAP-based financial performance measures, including revenues and net income / (loss).

We calculate forward-looking adjusted EBITDA, adjusted EBITDA margin, free cash flow, and free cash flow margin based on internal forecasts that omit certain amounts that would be included in forward-looking GAAP net income / (loss). We do not attempt to provide a reconciliation of forward-looking adjusted EBITDA, adjusted EBITDA margin, free cash flow, and free cash flow margin guidance and targets to forward-looking GAAP net income / (loss), GAAP net income / (loss) margin GAAP cash flows from operating activities, or GAAP cash flows from operating activities margin, respectively, because forecasting the timing or amount of items that have not yet occurred and are out of our control is inherently uncertain and unavailable without unreasonable efforts. Further, we believe that such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance.

 

Zeta Global Holdings Corp.

Condensed Unaudited Consolidated Balance Sheets

(In thousands)

 

 

As of

 

 

 

March 31, 2026

 

 

December 31, 2025

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

288,779

 

 

$

319,764

 

Accounts receivable

 

 

321,660

 

 

 

322,391

 

Prepaid expenses

 

 

32,257

 

 

 

28,970

 

Other current assets

 

 

6,616

 

 

 

14,658

 

Total current assets

 

$

649,312

 

 

$

685,783

 

Non-current assets:

 

 

 

 

 

 

Property and equipment, net

 

$

14,667

 

 

$

15,393

 

Website and software development costs, net

 

 

32,977

 

 

 

31,520

 

Right-to-use assets – operating leases, net

 

 

19,964

 

 

 

19,101

 

Intangible assets, net

 

 

202,855

 

 

 

217,943

 

Goodwill

 

 

522,007

 

 

 

527,886

 

Deferred tax assets, net

 

 

1,237

 

 

 

1,211

 

Other non-current assets

 

 

4,178

 

 

 

4,687

 

Total non-current assets

 

$

797,885

 

 

$

817,741

 

Total assets

 

$

1,447,197

 

 

$

1,503,524

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

32,158

 

 

$

40,136

 

Accrued expenses

 

 

173,033

 

 

 

179,087

 

Acquisition-related liabilities

 

 

47,875

 

 

 

149,036

 

Deferred revenue

 

 

37,430

 

 

 

35,398

 

Other current liabilities

 

 

23,714

 

 

 

25,824

 

Total current liabilities

 

$

314,210

 

 

$

429,481

 

Non-current liabilities:

 

 

 

 

 

 

Long-term borrowings

 

$

197,282

 

 

$

197,083

 

Acquisition-related liabilities

 

 

22,301

 

 

 

39,447

 

Deferred tax liabilities, net

 

 

17,784

 

 

 

17,268

 

Other non-current liabilities

 

 

15,295

 

 

 

15,656

 

Total non-current liabilities

 

$

252,662

 

 

$

269,454

 

Total liabilities

 

$

566,872

 

 

$

698,935

 

Stockholders’ equity:

 

 

 

 

 

 

Class A Common Stock

 

$

225

 

 

$

221

 

Class B Common Stock

 

 

24

 

 

 

24

 

Additional paid-in capital

 

 

1,958,549

 

 

 

1,863,695

 

Accumulated deficit

 

 

(1,073,064)

 

 

 

(1,059,817)

 

Accumulated other comprehensive (loss) / gain

 

 

(5,409)

 

 

 

466

 

Total stockholders’ equity

 

$

880,325

 

 

$

804,589

 

Total liabilities and stockholders’ equity

 

$

1,447,197

 

 

$

1,503,524

 

Condensed Unaudited Consolidated Statements of Operations and Comprehensive Loss

(In thousands)

 

 

Three months ended March 31,

 

 

 

2026

 

 

2025

 

Revenues

 

$

396,304

 

 

$

264,419

 

Operating expenses:

 

 

 

 

 

 

Cost of revenues (excluding depreciation and amortization)

 

 

162,446

 

 

 

103,488

 

General and administrative expenses

 

 

73,397

 

 

 

54,037

 

Selling and marketing expenses

 

 

102,403

 

 

 

75,369

 

Research and development expenses

 

 

44,950

 

 

 

26,799

 

Depreciation and amortization

 

 

23,529

 

 

 

17,687

 

Acquisition-related expenses

 

 

1,666

 

 

 

 

Restructuring expenses

 

 

6,752

 

 

 

3,152

 

Total operating expenses

 

$

415,143

 

 

$

280,532

 

Loss from operations

 

 

(18,839)

 

 

 

(16,113)

 

Interest expenses, net

 

 

761

 

 

 

331

 

Other (income) / expenses

 

 

(3,776)

 

 

 

3,512

 

Total other (income) / expenses

 

$

(3,015)

 

 

$

3,843

 

Loss before income taxes

 

 

(15,824)

 

 

 

(19,956)

 

Income tax (benefit) / provision

 

 

(2,577)

 

 

 

1,644

 

Net loss

 

$

(13,247)

 

 

$

(21,600)

 

 

The Company recorded stock-based compensation under respective lines of the above condensed unaudited consolidated statements of operations and comprehensive loss:

 

 

Three months ended March 31,

 

 

 

2026

 

 

2025

 

Cost of revenues (excluding depreciation and amortization)

 

$

270

 

 

$

261

 

General and administrative expenses

 

 

14,778

 

 

 

15,419

 

Selling and marketing expenses

 

 

25,156

 

 

 

19,545

 

Research and development expenses

 

 

12,828

 

 

 

6,762

 

Total

 

$

53,032

 

 

$

41,987

 

 

Condensed Unaudited Consolidated Statements of Cash Flows

(In thousands)

 

 

Three months ended March 31,

 

 

 

2026

 

 

2025

 

Cash flows from operating activities:

 

 

 

 

 

 

Net loss

 

$

(13,247)

 

 

$

(21,600)

 

Adjustments to reconcile net loss to net cash provided by operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 

23,529

 

 

 

17,687

 

Stock-based compensation

 

 

53,032

 

 

 

41,987

 

Deferred income taxes

 

 

126

 

 

 

(235)

 

Change in fair value of acquisition-related liabilities

 

 

(4,744)

 

 

 

3,460

 

Others, net

 

 

(157)

 

 

 

(519)

 

Change in non-cash working capital (net of acquisitions):

 

 

 

 

 

 

Accounts receivable

 

 

730

 

 

 

11,397

 

Prepaid expenses

 

 

(3,118)

 

 

 

2,219

 

Other current assets

 

 

8,057

 

 

 

(730)

 

Other non-current assets

 

 

509

 

 

 

15

 

Deferred revenue

 

 

1,920

 

 

 

(4,336)

 

Accounts payable

 

 

(8,114)

 

 

 

(11,053)

 

Accrued expenses and other current liabilities

 

 

(8,409)

 

 

 

(3,728)

 

Other non-current liabilities

 

 

(380)

 

 

 

235

 

Net cash provided by operating activities

 

$

49,734

 

 

$

34,799

 

Cash flows from investing activities:

 

 

 

 

 

 

Capital expenditures

 

 

(3,012)

 

 

 

(2,736)

 

Website and software development costs

 

 

(5,542)

 

 

 

(4,155)

 

Acquisitions and other investments, net of cash acquired

 

 

(47,000)

 

 

 

(530)

 

Net cash used for investing activities

 

$

(55,554)

 

 

$

(7,421)

 

Cash flows from financing activities:

 

 

 

 

 

 

Cash paid for acquisition-related liabilities

 

 

(241)

 

 

 

(3,667)

 

Proceeds from credit facilities, net of issuance cost

 

 

10,000

 

 

 

6,250

 

Exercise of options

 

 

302

 

 

 

123

 

Repurchase of shares

 

 

(25,728)

 

 

 

(25,882)

 

Repayments against the credit facilities

 

 

(10,000)

 

 

 

(6,250)

 

Net cash used for financing activities

 

$

(25,667)

 

 

$

(29,426)

 

Effect of exchange rate changes on cash and cash equivalents

 

 

502

 

 

 

289

 

Net decrease in cash and cash equivalents

 

$

(30,985)

 

 

$

(1,759)

 

Cash and cash equivalents, beginning of period

 

 

319,764

 

 

 

366,157

 

Cash and cash equivalents, end of period

 

$

288,779

 

 

$

364,398

 

 

Reconciliation of GAAP to Non-GAAP Financial Measures

(In thousands)

The following table reconciles adjusted EBITDA and adjusted EBITDA margin to net loss and net loss margin, respectively, the most directly comparable financial measure calculated and presented in accordance with GAAP.

 

 

Three months ended March 31,

 

 

 

2026

 

 

2025

 

Net loss

 

$

(13,247)

 

 

$

(21,600)

 

Net loss margin

 

 

(3.3)%

 

 

 

(8.2)%

 

Add back:

 

 

 

 

 

 

Depreciation and amortization

 

 

23,529

 

 

 

17,687

 

Acquisition-related expenses

 

 

1,666

 

 

 

 

Restructuring expenses

 

 

6,752

 

 

 

3,152

 

Stock-based compensation

 

 

53,032

 

 

 

41,987

 

Other (income) / expenses

 

 

(3,776)

 

 

 

3,512

 

Interest expenses, net

 

 

761

 

 

 

331

 

Income tax (benefit) / provision

 

 

(2,577)

 

 

 

1,644

 

Adjusted EBITDA

 

$

66,140

 

 

$

46,713

 

Adjusted EBITDA margin

 

 

16.7%

 

 

 

17.7%

 

 

The following table reconciles net cash provided by operating activities in the condensed unaudited consolidated statements of cash flows to free cash flow:

 

 

Three months ended March 31,

 

 

 

2026

 

 

2025

 

Net cash provided by operating activities

 

$

49,734

 

 

$

34,799

 

Capital expenditures

 

 

(3,012)

 

 

 

(2,736)

 

Website and software development costs

 

 

(5,542)

 

 

 

(4,155)

 

Effect of exchange rate changes on cash and cash equivalents

 

 

502

 

 

 

289

 

Free cash flow

 

$

41,682

 

 

$

28,197

 

Free cash flow margin

 

 

10.5%

 

 

 

10.7%

 

 

Investor Relations

Matt Pfau

[email protected]

Press

Candace Dean

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Software Mobile/Wireless Internet Professional Services Technology Artificial Intelligence Other Communications Publishing Marketing Advertising Communications Finance

MEDIA:

Logo
Logo

Revvity Board Declares Quarterly Dividend

Revvity Board Declares Quarterly Dividend

WALTHAM, Mass.–(BUSINESS WIRE)–
The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 7, 2026 to all shareholders of record at the close of business on July 17, 2026.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

Media Relations:

Chet Murray

(781) 462-5126

[email protected]

Investor Relations:

Steve Willoughby

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Technology Pharmaceutical Other Science Research Medical Devices Healthcare Reform Public Policy/Government Children Baby/Maternity Biotechnology Health Satellite General Health Science Other Manufacturing Consumer Packaging Software Engineering Hardware Manufacturing Other Health Consumer Electronics Other Policy Issues

MEDIA:

Logo
Logo

Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection

  • Ongoing Phase 1b human challenge study with oral, direct-acting protease inhibitor is designed to demonstrate proof-of-concept as a preventive and a treatment
  • Fully enrolled first cohort is assessing the infectivity of the human challenge inoculum
  • There are no approved treatments or vaccines for norovirus, the leading cause of acute gastroenteritis across all age groups and geographies with a $60 billion annual economic burden
  • FDA Fast Track designation granted for CDI-988 underscores the lack of approved therapies and seriousness of norovirus infection

BOTHELL, Wash., April 30, 2026 (GLOBE NEWSWIRE) —
Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that the mechanism of action and clinical advancement of its first oral protease inhibitor CDI-988 were featured today in an oral presentation at the 39th International Conference on Antiviral Research (ICAR 2026) in Prague, Czech Republic. The presentation, titled “First Oral Direct-Acting Antiviral CDI-988 for Norovirus Infection Prevention and Treatment: Novel Mechanism of Action and Phase 1 Study Results,” was delivered by Sam Lee, Ph.D., President and co-CEO of Cocrystal. Presentation slides are available on the Company’s website here.

“It was an honor to share our progress with CDI-988 with the global antiviral research community attending ICAR 2026,” said Dr. Lee. “Following favorable Phase 1 data, we have advanced CDI-988 into a Phase 1b study under a human challenge model that provides an efficient framework to rapidly demonstrate proof of concept as a preventive and as a treatment for norovirus infection. We have now completed enrollment of the stage 1 study cohort, which will establish the infectivity rate of the GII.2 (Snow Mountain Virus) challenge inoculum. This is a critical step in validating infectivity in the study cohorts.

“Multiple norovirus vaccine clinical studies have been initiated over the past decade, yet none have led to an approval in part due to the virus’s extensive genetic variation and drift, spanning 10 genogroups and 49 genotypes,” Dr. Lee added. “CDI-988 is designed to target the highly conserved region of the 3CL protease across all known norovirus strains, including GII.4 and the re-emerging GII.17 variants, as well as all coronaviruses. We believe this compound could offer a much‑needed option for prevention and treatment in a convenient oral formulation that can be readily stockpiled in advance of norovirus outbreaks.”

CDI-988 is a first, oral direct-acting antiviral and was developed using Cocrystal’s proprietary structure-based drug discovery platform technology. As presented by Dr. Lee, in preclinical studies CDI-988 showed favorable gastrointestinal-targeted pharmacokinetics at the site of norovirus infection and also demonstrated potent antiviral activity in GII.4-infected human enteronoid model systems.

In a completed randomized, double‑blind, placebo‑controlled single‑ and multiple‑ascending dose Phase 1 study in healthy adults, CDI‑988 was generally safe and well tolerated across doses up to 1,200 mg, with headache as the most common treatment‑emergent adverse event and no serious adverse events reported. These results, together with a no-observed adverse effect of 1,000 mg/kg in GLP toxicology studies, support CDI-988’s further clinical development in norovirus.

The ongoing Phase 1b randomized, double‑blind, placebo‑controlled challenge study (NCT07198139) is being conducted at Emory University School of Medicine in collaboration with the University of North Carolina. The study is designed to enroll up to 40 healthy adults, ages 18 to 49, in staged cohorts. The stage 1 infectivity cohort, now fully enrolled, will be followed by prevention and treatment cohorts in which CDI‑988 is administered at 1,200 mg twice daily for five days. The primary efficacy endpoint is reduction in the incidence of clinical symptoms, with secondary endpoints including reduction in viral shedding, disease severity, safety and pharmacokinetics.

CDI‑988 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment and prophylaxis of norovirus infection, underscoring the serious nature of norovirus disease and the lack of approved therapies. Fast Track status is intended to facilitate development and expedite the review of drugs that address unmet medical needs, providing opportunities for more frequent FDA interactions, rolling review of a potential New Drug Application and potential eligibility for Priority Review.

About Norovirus

Norovirus is the leading cause of acute gastroenteritis among all age groups and all geographic regions. It is highly contagious and causes symptoms including nausea, vomiting, stomach pain, diarrhea, fatigue, fever and dehydration. It is notorious for outbreaks in semi-closed environments such as hospitals, nursing homes, cruise ships, schools and military facilities. Norovirus is responsible for an estimated 685 million cases and an estimated 200,000 deaths globally each year, with an approximate $60 billion in worldwide economic impact. In the United States alone, the virus is associated with 21 million infections annually, resulting in around 109,000 hospitalizations, 465,000 emergency department visits and 900 deaths. The estimated annual economic burden in the U.S. exceeds $10.6 billion. In developing nations, norovirus contributes up to 1.1 million hospitalizations and 218,000 pediatric deaths each year.

About ICAR

Hosted by the International Society for Antiviral Research (ISAR), the International Conference on Antiviral Research (ICAR) brings together leading scientists, researchers and industry professionals from around the world to discuss the latest advancements and breakthroughs in antiviral research. ICAR provides a variety of networking opportunities allowing members to connect with colleagues and establish new scientific relationships and collaborations with leaders in the antiviral field.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of noroviruses, influenza viruses, coronaviruses (including SARS-CoV-2), and rhinoviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create viable antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding any implications that CDI-988 is able to prevent and/or treat norovirus infections. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks and uncertainties arising from delays arising from raw materials and labor shortages, supply chain disruptions and other business interruptions including any adverse impacts on our ability to obtain raw materials for and otherwise proceed with studies as well as similar problems with our vendors and our current and any future clinical research organization (CROs) and contract manufacturing organizations, the progress and results of the studies including any adverse findings or delays, the ability of us and our CROs to recruit volunteers for, and to otherwise proceed with, clinical studies, our and our collaboration partners’ technology and software performing as expected, financial difficulties experienced by certain partners, the results of any current and future preclinical and clinical studies, general risks arising from clinical studies, receipt of regulatory approvals, regulatory changes and any adverse developments which may arise therefrom, and general economic adverse effects from the ongoing conflict with Iran. Further information on our risk factors is contained in our filings with the SEC, including the “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:

Alliance Advisors IR
Jody Cain
310-691-7100
[email protected]

# # #



CitroTech to Host First Quarter 2026 Financial Results Conference Call on May 15, 2026

CitroTech to Host First Quarter 2026 Financial Results Conference Call on May 15, 2026

DENVER–(BUSINESS WIRE)–
CitroTech Inc. (NYSE AM: CITR), a leading specialty chemical company delivering environmentally-safe fire inhibitor solutions, today announced that management will host a conference call on Friday, May 15, 2026 at 9:00 a.m. Eastern Time to discuss CitroTech’s 2026 first quarter financial results with the investment community. The company will release results for the first quarter ended March 31, 2026 on Friday, May 15, 2026, before the markets open.

Anyone interested in participating should call 1-877-407-3982 if calling within the United States or 1-201-493-6780 if calling internationally. When asked, please reference confirmation code 13760448.

A replay will be available until Friday, May 29, 2026, which can be accessed by dialing 1-844-512-2921 if calling within the United States or 1-412-317-6671 if calling internationally. Please use passcode 13760448 to access the replay.

The call will also be accompanied live by webcast over the Internet and accessible at https://viavid.webcasts.com/starthere.jsp?ei=1762067&tp_key=c913f46bf3.

About CitroTech Inc.

CitroTech Inc. (NYSE AM: CITR) is manufacturing and deploying the CitroTech family of innovative, environmentally safe fire prevention solutions for homes, wood products, and wildfire prevention and asset protection. CitroTech is the only long-term fire inhibitor recognized by the EPA Safer Choice program and tested to UL Greenguard Gold standards, providing effective and scientifically validated wildfire mitigation while safeguarding human and environmental health. The company’s growing patent portfolio, recurring-revenue model, and scalable approach support its long-term growth and market expansion. For more information, visit www.citrotech.com.

Media & Investor Contact:

CitroTech Inc.

Isabella Sarlo

Antenna Group

[email protected]

(516) 526-9227

Investor Relations Contact:

Brett Maas, Managing Principal

Hayden IR, LLC

[email protected]

(480) 861-2425

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: Environmental Issues Natural Disasters Building Systems Environment Construction & Property

MEDIA:

Logo
Logo

Eaton Vance Limited Duration Income Fund, Eaton Vance Senior Floating-Rate Trust, and Eaton Vance Senior Income Trust Announce Tender Offers for Outstanding Auction Preferred Shares

Eaton Vance Limited Duration Income Fund, Eaton Vance Senior Floating-Rate Trust, and Eaton Vance Senior Income Trust Announce Tender Offers for Outstanding Auction Preferred Shares

BOSTON–(BUSINESS WIRE)–
Eaton Vance Limited Duration Income Fund (NYSE American: EVV), Eaton Vance Senior Floating-Rate Trust (NYSE: EFR), and Eaton Vance Senior Income Trust (NYSE: EVF) (each a “Fund,” and together, the “Funds”) announced that each Fund today commenced a voluntary tender offer (each, a “Tender Offer” and together, the “Tender Offers”) for up to 100% of its outstanding auction preferred shares (“APS”) at a price per share equal to 98% of the APS liquidation preference of $25,000 per share (or $24,500 per share), plus any unpaid APS dividends accrued through the expiration date of the Tender Offer. Each Fund’s Tender Offer will expire at 5:00 P.M., New York City Time, on May 29, 2026, unless otherwise extended. It is expected that the payment of the Tender Offer proceeds will be made as soon as practicable after the expiration date of the Tender Offers, or such later date to which the Tender Offers may be extended.

This announcement is not a recommendation, an offer to purchase, or a solicitation of an offer to sell APS of the Funds. The Funds will file with the Securities and Exchange Commission a tender offer statement on Schedule TO and related exhibits, including an offer to purchase, a related letter of transmittal and other related documents (the “Tender Offer Documents”). The Tender Offer Documents were mailed or distributed electronically to APS holders starting today. Each Fund’s Tender Offer is conditioned on certain conditions as set forth in the Tender Offer Documents. Preferred shareholders of the Funds should read the Tender Offer Documents carefully as they contain important information about the Tender Offers. Preferred Shareholders of the Funds can also obtain a free copy of the Tender Offer Documents at the SEC’s website at www.sec.gov. APS holders may obtain further information regarding the Tender Offers by calling EQ Fund Solutions, LLC, the Funds’ information agent for the Tender Offers, at (877) 732-3614.

About the Funds

Shares of closed-end funds often trade at a discount from their net asset value. The market price of each Fund’s shares may vary from net asset value based on factors affecting the supply and demand for shares, such as Fund distribution rates relative to similar investments, investors’ expectations for future distribution changes, the clarity of each Fund’s investment strategy and future return expectations, and investors’ confidence in the underlying markets in which each Fund invests. Fund shares are subject to investment risk, including possible loss of principal invested. The Funds are not a complete investment program and you may lose money investing in the Funds. An investment in a Fund may not be appropriate for all investors. Before investing, prospective investors should consider carefully each Fund’s investment objective, risks, charges and expenses.

Eaton Vance is part of Morgan Stanley Investment Management, the asset management division of Morgan Stanley.

About Morgan Stanley Investment Management

Morgan Stanley Investment Management, together with its investment advisory affiliates, has more than 1,300 investment professionals around the world and $1.9 trillion in assets under management or supervision as of March 31, 2026. Morgan Stanley Investment Management strives to provide outstanding long-term investment performance, service, and a comprehensive suite of investment management solutions to a diverse client base, which includes governments, institutions, corporations and individuals worldwide. For further information about Morgan Stanley Investment Management, please visit www.morganstanley.com/im.

About Morgan Stanley

Morgan Stanley (NYSE: MS) is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With offices in 42 countries, the Firm’s employees serve clients worldwide including corporations, governments, institutions and individuals. For more information about Morgan Stanley, please visit www.morganstanley.com.

This press release is for informational purposes only and is not intended to, and does not, constitute an offer to purchase or sell shares of the Funds. Additional information about the Funds, including performance and portfolio characteristic information, is available at eatonvance.com.

Statements in this press release that are not historical facts are “forward-looking statements” as defined by the U.S. securities laws. You should exercise caution in interpreting and relying on forward-looking statements because they are subject to uncertainties and other factors which are, in some cases, beyond a Fund’s control and could cause actual results to differ materially from those set forth in the forward-looking statements. All forward-looking statements are as of the date of this release only; each Fund undertakes no obligation to update or review any forward-looking statements.

Investor Contact: (800) 262-1122

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

Griffon Corporation Schedules Conference Call To Discuss Second Quarter 2026 Financial Results

Griffon Corporation Schedules Conference Call To Discuss Second Quarter 2026 Financial Results

NEW YORK–(BUSINESS WIRE)–
Griffon Corporation (“Griffon” or the “Company”) (NYSE: GFF) today announced it will release the Company’s fiscal second quarter results on Thursday, May 7, 2026, followed by a conference call at 8:30 AM ET.

The call can be accessed by dialing 1-877-407-0792 (U.S. participants) or 1-201-689-8263 (International participants). Callers should ask to be connected to the Griffon Corporation teleconference or provide conference ID number 13759508. Participants are encouraged to dial-in at least 10 minutes before the scheduled start time.

A replay of the call will be available starting on Thursday, May 7, 2026, at 11:30 AM ET by dialing 1-844-512-2921 (U.S.) or 1-412-317-6671 (International) and entering the conference ID number: 13759508. The replay will be available through Thursday, May 21, 2026, at 11:59 PM ET.

About Griffon Corporation

Griffon is a diversified management and holding company that conducts business through wholly-owned subsidiaries. Griffon oversees the operations of its subsidiaries, allocates resources among them and manages their capital structures. Griffon provides direction and assistance to its subsidiaries in connection with acquisition and growth opportunities as well as divestitures. As long-term investors, we intend to continue to grow and strengthen our existing businesses, and to diversify further through investments in our businesses and acquisitions.

Griffon conducts its operations through two reportable segments:

  • Home and Building Products conducts its operations through Clopay Corporation (“Clopay”). Founded in 1964, Clopay is the largest manufacturer and marketer of garage doors and rolling steel doors in North America. Residential and commercial sectional garage doors are sold through professional dealers and leading home center retail chains throughout North America under the brands Clopay, Ideal, and Holmes. Rolling steel door and grille products designed for commercial, industrial, institutional, and retail use are sold under the Clopay, Cornell and Cookson brands.
  • Consumer and Professional Products (“CPP”) is a global provider of branded consumer and professional tools; residential, industrial and commercial fans; home storage and organization products; and products that enhance indoor and outdoor lifestyles. CPP sells products globally through a portfolio of leading brands including AMES, since 1774, Hunter, since 1886, True Temper, and ClosetMaid.

For more information on Griffon and its operating subsidiaries, please see the Company’s website at www.griffon.com.

Company Contact:

Brian G. Harris

EVP & Chief Financial Officer

Griffon Corporation

(212) 957-5000

Investor Relations Contact:

Tom Cook

Managing Director

ICR Inc.

(203) 682-8250

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Finance Professional Services Residential Building & Real Estate Commercial Building & Real Estate Construction & Property

MEDIA: